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ABSTRACT OF DISSERTATION

NOVEL POST-TRANSLATIONAL MODIFICATION AND FUNCTION
OF FUS: THE RELEVANCE TO AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease
characterized by the preferential death of motor neurons. Approximately 10% of
ALS cases are familial and 90% are sporadic. Fused in Sarcoma (FUS) is a
ubiquitously expressed RNA binding protein implicated in familial ALS and
frontotemporal dementia (FTD). FUS is ubiquitously expressed in cells and has a
variety of functions in the nucleus and cytoplasm. FUS mutations in the nuclear
localization sequence (NLS) causes mislocalization of FUS in the cytoplasm,
where it can undergo liquid-liquid phase separation and become stress granules
or protein inclusions. Although FUS inclusion bodies can be found in post-mortem
tissues from ALS patients, the pathological mechanism of the disease remains to
be fully elucidated.
This dissertation includes two independent studies about FUS regulation and
function in the cell. In the first study, we discovered a novel post-translational
modification, i.e. lysine acetylation on FUS and aimed to understand whether
lysine acetylation plays a role in regulating FUS function. We identified three
acetylation sites in FUS: K315/K316 in the RRM domain and K510 in the NLS. We
found that K510 disrupted the interaction with Transportin-1 and increased
cytoplasmic protein aggregates that co-localized with stress granule markers.
Interestingly, acetylation in K315/K316 reduced RNA binding to FUS and
decreased the cytoplasmic inclusion formation. Similarly, treatment with
deacetylase inhibitors also decreased protein aggregation in cells expressing ALS
mutation P525L. Furthermore, ALS patient derived fibroblasts showed higher
levels of acetylation at K510, compared to healthy controls. Finally, we
demonstrated that CBP/p300 acetylates FUS, while both HDACs and Sirtuins
contribute to FUS deacetylation. We concluded that FUS acetylation regulates
RNA binding, subcellular localization, and inclusion formation, linking acetylation
of FUS to a potential molecular mechanism for ALS/FTD.

The second study aimed to determine the function of FUS in the autophagy
pathway. We found that mutant FUS did not affect autophagy flux in N2A cells.
However, FUS knockout (KO) N2A cells showed a significant decrease in the basal
autophagy flux compared to wild-type (WT) cells. Bafilomycin A1 treatment
showed a decrease in autophagy flux in FUS KO cells, and induction of autophagy
by rapamycin was not as efficient in FUS KO cells compared to WT cells. These
results suggest that FUS KO affects early stages of the autophagy pathway. We
found that FIP200, ATG16L1, and ATG12 gene and protein expression levels were
significantly lower in FUS KO cells. FIP200 is involved in autophagy initiation and
Atg16 and Atg12 form a complex to induce phagophore elongation.
Overexpressing WT FUS in FUS KO cells was able to rescue gene and protein
expression levels of FIP200 and ATG16L1. These findings demonstrate a novel
function of FUS in regulating transcription of genes involved in early stages of the
autophagy pathway. Failure to maintain protein homeostasis by protein
degradation has been demonstrated in neurodegenerative diseases and finding
new protein targets can be useful to discover new therapeutic options for ALS.
The two studies of this dissertation produce novel findings of FUS protein
modification and function. Each study provides new insights into the role of FUS in
neurodegenerative diseases including ALS and FTD, as well as novel therapeutic
targets. Future studies that determine the molecular mechanisms connecting
these two findings will be necessary to evaluate how FUS acetylation and inclusion
formation will impact the autophagy pathway.
KEYWORDS: FUS, lysine acetylation, autophagy, stress granules, cytoplasmic
inclusions, RNA-binding
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CHAPTER 1. LYSINE ACETYLATION REGULATES THE RNA BINDING,
SUBCELLULAR LOCALIZATION AND INCLUSION FORMATION OF FUS
Modified from the manuscript “Lysine acetylation regulates the RNA
binding, subcellular localization and inclusion formation of FUS” published in
Human Molecular Genetics, 21 July 2020. PMID: 32691043
https://doi.org/10.1093/hmg/ddaa159
1.1

Abstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease
characterized by the preferential death of motor neurons. Approximately 10%
of ALS cases are familial and 90% are sporadic. Fused in Sarcoma (FUS) is a
ubiquitously expressed RNA binding protein implicated in familial ALS and
frontotemporal dementia (FTD). The physiological function and pathological
mechanism of FUS are not well understood, particularly whether posttranslational modifications play a role in regulating FUS function. In this study,
we discovered that FUS was acetylated at lysine-315/316 (K315/K316) and
lysine-510 (K510) residues in two distinct domains. Located in the nuclear
localization sequence, K510 acetylation disrupted the interaction between
FUS and Transportin-1, resulting in the mis-localization of FUS in the
cytoplasm and formation of stress granule-like inclusions. Located in the RNA
recognition motif, K315/K316 acetylation reduced RNA binding to FUS and
decreased the formation of

cytoplasmic inclusions. Treatment with

deacetylase inhibitors also significantly reduced the inclusion formation in cells
expressing ALS mutation P525L. More interestingly, familial ALS patient
fibroblasts showed higher levels of FUS K510 acetylation as compared to
healthy controls. Lastly, CBP/p300 acetylated FUS, whereas both SIRT and
1

HDAC families of lysine deacetylases contributed to FUS deacetylation. These
findings demonstrate that FUS acetylation regulates the RNA binding,
subcellular localization, and inclusion formation of FUS, implicating a potential
role of acetylation in the pathophysiological process leading to FUS-mediated
ALS/FTD.

1.2

Introduction

1.2.1 Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurological
disorder characterized by the gradual degeneration of motor neurons leading
to progressive weakening of muscles, paralysis and death [1]. Motor neurons
are cells that reach the brain, brain stem, and spinal cord, and they
communicate the nervous system with the voluntary muscles of the body [1].
In ALS, when motor neurons degenerate and die, signals from the brain are
unable to reach the muscles, and as a consequence, the muscles waste away
and patients lose their ability to move their arms and legs, to talk, and to
breathe. Eventually, patients need respiratory support, and most people die
from respiratory failure or pneumonia [2].

1.2.2 Epidemiology of ALS
According to the ALS association, more than 5,000 people are
diagnosed with ALS each year, and about 16,000 people live with ALS at any
2

given time in the United States [3]. The National ALS registry reported that the
prevalence of ALS in the United States was 5.2 per 100,000 population in 2015
[3]. The median age of ALS diagnosis is between 54 and 69 years old [4], and
the median survival from the symptoms onset is approximately 2-3 years. The
ratio of cases between males and females is 1.6:1 [3]. The ratio of cases
between Caucasians and African Americans is approximately 2.3:1 in the
United States [3]. Interestingly, there is evidence supporting that people who
serve in the military have a higher risk of developing ALS [5]. In addition,
smoking, head trauma, exposure to lead and other heavy metals, and
exposure to agricultural chemicals are considered potential risk factors of
developing ALS [6]. However, the relationship between the environmental
factors and development of the disease has been difficult to identify because
most of the times, the environmental exposure can change over time and may
not have been accurately recorded [7].

1.2.3 Sporadic and familial ALS
ALS was initially considered a sporadic disease as Jean-Martin Charcot
initially supported the notion [8]. Years later, there was a report of a family in
Vermont with autosomal dominant inheritance of ALS [9]. Nowadays, it has
been shown that most cases of ALS are sporadic (~ 90%), while the remaining
10% of the cases are inherited [2, 3]. The clinical characteristics of ALS are
similar whether it is inherited or sporadic [10]. Studying familial cases of ALS
allows to gain insights about the pathology of the disease in general, and it will
3

likely benefit patients with sporadic forms of ALS. Mutations in several genes
have been identified to cause the familial form of ALS (fALS) [4]. For instance,
an hexanucleotide repeat expansion in the chromosome 9 open reading frame
72 gene (C9orf72) accounts for about 30%-40% of the familial cases of ALS
[11, 12]. Generally, a person has 30 or fewer GGGGCC repeats. However ALS
or frontotemporal degeneration (FTD) patients may carry hundreds or
thousands of GGGGCC repeats, and these expansions are often associated
with behavioral changes [7]. Copper-zinc superoxide dismutase (SOD1), is an
antioxidant enzyme that protects cells against superoxide radicals and reactive
oxygen species (ROS) [13]. About 20% of familial cases of ALS have
mutations in SOD1 [2]. Many studies suggest that SOD1 mutations cause ALS
in a gain-of-function manner. The first supporting evidence was done in a
transgenic mouse model expressing the point mutation G93A SOD1 [14]. The
mice showed motor neuron loss and became paralyzed by 5-6 months of age
[14]. Additional studies of transgenic mice expressing other human SOD1
mutations show an adult-onset phenotype along with a loss of lower motor
neurons [15]. Nonetheless, it was also proposed that the loss-of-function might
play a minor role in the disease [16].
Another gene involved in familial ALS is TARDBP, the gene that
encodes the TAR DNA-binding protein 43 (TDP-43). Mutations in this gene
account for 4% of familial ALS and 1% of sporadic ALS cases [10]. However,
approximately 97% of ALS cases, including familial and sporadic, show TDP43-positive inclusions. The TDP-43 proteinopathy [17] is characterized by the
4

exclusion of TDP-43 from the nucleus and the deposition of full-length and
fragmented TDP-43 in cytoplasmic aggregates that are also ubiquitinated and
hyperphosphorylated [18]. TDP-43 is a DNA/RNA binding protein that has the
ability to shuttle between the nucleus and the cytoplasm [19]. In the nucleus it
has been reported to be involved in transcription and splicing [17, 20]. In the
cytoplasm it has a role in RNA transport [21] and stress granule response [22].
It is unclear whether TDP-43 causes ALS by a gain or loss of function.
A few studies show that TDP-43 overexpression mimics the disease
phenotype in transgenic mice models [23, 24]. However, conditional TDP-43
KO mouse models have demonstrated that loss of TDP-43 also causes motor
neuron degeneration, very similar to the human phenotype along with TDP-43
proteinopathy [25, 26]. Currently, it is considered in the field that both
mechanisms may contribute to the development of the disease [17, 27].
Furthermore, mutations in Fused in Sarcoma (FUS, also called
Translocated in Liposarcoma or TLS) are found in about 5% of the familial
cases of ALS [28]. FUS pathology and mutations have also been reported in
sporadic ALS cases [28-31]. Mutations in the FUS gene are associated with
juvenile and young adult cases of sporadic ALS [32-34]. Moreover, FUS
pathology is reported in approximately 10% cases of another clinically
overlapping disease frontotemporal dementia (FTD-FUS) [30]. FUS is also a
DNA/RNA binding protein with diverse functions in the cell [35]. Our lab
focuses on the function of FUS and how mutations and post-translational
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modifications affect the function of this protein and its association with the
development of ALS and FTD.

1.2.4 Fused in Sarcoma (FUS)
FUS is a ubiquitously expressed RNA-binding protein that plays a role
in different cellular processes such as DNA repair [36-38], transcription [3949], RNA splicing [48, 50, 51], nucleo-cytoplasmic RNA shuttling [52] and
dendritic RNA transport [53-55]. FUS contains a very transcriptionally active
N-terminal prion-like domain, (QGSY-rich), an RNA recognition motif (RRM),
a zinc finger domain flanked by two Arginine-Glycine-Glycine (RGG)-rich
domains, a nuclear export sequence (NES), and a C-terminal nuclear
localization sequence (NLS) [27] (Figure 1.1). FUS is mainly localized in the
nucleus, although it is also present in the cytoplasm of neuronal cells at lower
levels [28]. Many of the fALS–related FUS mutations are localized in the Cterminal NLS, causing mis-localization of FUS to the cytoplasm where it forms
stress granule-like structures [29-32]. A loss of FUS function in the nucleus
and a gain of toxic function in the cytoplasm can both contribute to the disease
mechanism concomitantly [33].

1.2.5 Physiological roles of FUS in the nucleus
Several groups have characterized the functions of FUS in the cell.
Since FUS localizes mainly in the nucleus, it has been reported to play crucial
6

roles in transcription, miRNA processing, splicing, and DNA damage
response. For instance, FUS has been reported to bind DNA and RNA through
their RRM domain, the RGG-rich domain, and the zinc finger domains [36, 56,
57]. A common ‘GGUG’ RNA consensus sequence has been identified to bind
FUS [56], but more recent studies have reported that FUS can bind G/C or A/C
rich regions [58, 59]. Another study confirmed that FUS binds long regions in
the 3’ UTR of Nd1-L mRNA [53], suggesting that FUS can recognize other
RNA binding domains from other proteins and bind to secondary structures.
Additionally, FUS also plays a role in transcription. Numerous studies
have found that FUS interacts with transcription factors [49, 60] hormone
receptors [61], and the transcriptional machinery that includes RNA
polymerase II and the TFIID complex [62, 63]. Similarly, FUS has been shown
to repress transcription of Cyclin D1 in response to DNA damage, by being
recruited into the promoter region, and inhibiting the activity of the
acetyltransferases CREB-binding protein (CBP) and p300 on Cyclin D1 [39].
Another study reported that FUS N-terminal QGSY-rich region is required for
active-chromatin binding, and for transcription activation of MnSOD and
histone-lysine N-methyltransferase, SMYD3. The same study added that FUS’
self-assembly is necessary for chromatin binding, and that FUS ALS mutants
disrupt these functions [48]. These data show that FUS is capable of binding
RNA, transcriptional machinery, and active chromatin, having a relevant role
in gene transcription.

7

Similarly, FUS has been found to be involved in microRNA (miRNA)
processing. There is evidence that miRNAs might play a protective role in
motor neurons and promote motor neuron survival [64, 65]. Specifically, mice
that lacked miR-218 died at birth with motor neuron defects [66]. Additionally,
motor neurons derived from a spinal muscular atrophy patient showed
downregulation of miR-375, and these motor neurons were highly susceptible
to DNA damage [65]. Moreover, in a transcriptome analysis, miR-375 was
deregulated in mutant FUS motor neurons, while toxic expression of apoptotic
factor p53 and neural RNA-binding protein ELAVL4, increased significantly in
FUS mutants [67]. FUS has been directly associated to miRNA biogenesis by
enabling the recruitment of the enzyme Drosha to chromatin transcription
sites, and by interacting with nascent pri-miRNAs, in order to allow effective
miRNA processing [68]. Together, these studies show that FUS plays an
important role in miRNA biogenesis, having an impact in post-transcriptional
gene regulation.
Furthermore, FUS is involved in alternative splicing. Proteomics studies
have found that FUS is present in the spliceosome [69, 70]. Also, sequencing
analysis have showed that FUS is enriched in exons that are actively
undergoing alternative splicing [59, 71]. Interestingly, a group found that FUS
binds to a conserved region in exon 7 of its own pre-mRNA. [72]. The study
showed that FUS overexpression caused inhibition of exon 7 splicing and
downregulation of endogenous FUS protein levels, showing a mechanism for
FUS autoregulation. In contrast, cytoplasmic FUS mutants were unable to
8

repress exon 7 splicing and regulate protein expression [72], showing that FUS
nuclear localization is necessary for alternative splicing and FUS
autoregulation.
Additionally, FUS interacts with alternative splicing regulators such as
SMN (survival motor neuron), and U1 snRNP [73]. SMN is highly expressed in
spinal cord and brainstem, and mutations in this protein cause Spinal Muscular
Atrophy (SMA)[74] . SMN is part of a complex that plays an important role in
mRNA processing [75]. In the cells, this protein localizes to nuclear gems,
which are nuclear structures where small nuclear ribonucleoprotein (snRNP)
maturation takes place [74]. The relationship between FUS and SMN has been
widely studied, since

these two

proteins

have a

crucial role

in

neurodegeneration. Specifically, ALS-associated FUS mutations sequester
SMN into cytoplasmic inclusions, inhibiting the function of SMN in the nucleus
and reducing the number of nuclear gems. Similarly, HeLa FUS knockout cells
also show loss of nuclear gems [73]. In a similar study, FUS ALS mutations
increased the interaction between FUS and SMN, causing a decrease in
number of nuclear gems and a lower levels of snRNAs [76]. These studies
demonstrate that FUS plays an important role in mRNA biogenesis and
splicing, and show that a gain of toxic function, along with a loss of nuclear
function can occur alongside and contribute to the disease phenotype.

9

1.2.6 Physiological roles of FUS in the cytoplasm.
FUS has the capacity of shuttling between the nucleus and the
cytoplasm, where it can regulate different facets of RNA metabolism such as
protein translation, RNA stability, RNA transport, or stress granule formation.
The involvement of FUS in RNA transport has been reported in various
studies. For example, a proteomics study found that FUS interacts with kinesin
KIF5, a protein that is part of an RNA-transporting granule [77]. Additionally,
another study showed that following NMDA activation, FUS requires actin
filaments and microtubules to translocate to dendritic spines and is involved in
preserving spine morphology and stabilizing synaptic structure by transporting
mRNAs that encode for Nd1-L, an actin-stabilizing protein. [53, 54]. These
studies show that FUS has an important role in transporting RNA to active
translation spots in the cytoplasm, and this function is crucial for the good
development of neuronal cells.
An early study found that FUS associates with adenomatous polyposis
coli (APC), and it is required for translation of APC-ribonucleoprotein (APCRNPs) transcripts in cell protrusions [78]. They show that aggregates formed
as a result of mutant FUS overexpression recruit APC-RNPs, and these
aggregates are transcriptionally active. Later on, a breakthrough mass
spectrometry study showed that FUS is involved in protein translation and nonsense mediated decay (NMD) [79]. They found that cytoplasmic mutant FUS
inclusions contained proteins involved in translation and RNA surveillance.
Furthermore, using a variety of assays, they proved that FUS ALS mutations
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impaired global protein translation. Additionally, they demonstrated that
translation initiation was not affected by FUS mutations. Interestingly, NMD
factors were disrupted in N2A cells overexpressing FUS mutants and in ALSpatients derived fibroblasts, leading to over activation of the NMD pathway.
This study suggests that FUS has an important role in protein biosynthesis and
mRNA quality control.
A more recent work using proteomics compared the translated
proteomes of WT and mutant FUS after being exposed to stress. They
identified a great number of neurodegeneration-related proteins that become
unregulated by avoiding stress induced translational repression [80]. One of
the target proteins they found to be downregulated in mutant FUS cells under
stress was COPB1, a protein involved in the retrograde transport between the
Golgi apparatus and the endoplasmic reticulum (ER), showing that vesicular
transport can also be impacted in FUS-ALS.
Cytoplasmic FUS is also involved in stress granule dynamics and
inclusion formation. WT cytoplasmic FUS can be chaperoned back to the
nucleus by Transportin-1 (TNPO1), through a direct interaction with FUS-NLS
[81]. Meanwhile, many FUS fALS-related mutations are localized in the Cterminal NLS, decreasing the binding affinity between FUS and TNPO1,
causing mis-localization of FUS to the cytoplasm where it can form inclusions
that co-localize with stress granule proteins [82-85]. Moreover, a study found
that patterns of aggregation in nuclear and cytoplasmic FUS are different [86].
The study showed that while nuclear FUS requires the QGSY-rich region to
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form nuclear granules [87], cytoplasmic FUS did not required the prion-like
domain to form mutant FUS cytoplasmic inclusions, suggesting that the
structure of these aggregates are different depending on their sub-cellular
localization. In fact, they showed that the nuclear compartment where FUS
aggregates are formed, contribute to their distribution pattern and behavior,
irrespective of WT or mutant FUS. In the same study, the authors found that
the RNA binding capability of FUS is required to form cytoplasmic inclusions,
and that chromatin related RNAs are crucial for FUS’ oligomerization [86].
Similarly, using a Drosophila model of ALS, a group generated mutants
deficient in RNA-binding. They found that RNA-binding deficient mutant FUS
was not able to incorporate into stress granules [88].

Stress granules are

believed to be a preceding event in inclusion formation, however, further
studies are necessary to understand how these structures become aberrant
for the cells, when mutant FUS is present.

1.2.7 FUS and Post-translational modifications
Post-translational modifications (PTMs) refer to covalent attachments
or proteolytic cleavages of a functional group to a protein after biosynthesis,
changing or regulating its subcellular functions and increasing the diversity of
the proteome [89]. Common eukaryotic PTMs include methylation,
phosphorylation, acetylation, ubiquitination, and sumoylation (34). Lysine
acetylation occurs when the acetyl group in acetyl-CoA is transferred to the εamino group of a lysine residue of a protein [90]. This process is reversible,
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and it is regulated by two types of enzymes: lysine acetyltransferases (HATs),
that add the acetyl group to the lysine residue, and lysine deacetylases
(HDACs) that remove it [90].
Lysine acetylation has many roles in the cells, however the effect of this
PTM on gene expression has been well characterized. It has been
demonstrated that when histone tails are acetylated, the interaction between
the histones and DNA backbone is disrupted, resulting in a relaxation of the
condensed chromatin, making it more accessible to the transcription
machinery [91]. However, lysine acetylation can regulate many other functions
in the cells. A proteomics study identified around 1750 proteins that can be
acetylated [92]. They also showed that lysine acetylation can be involved in
various cellular processes including RNA transcription, splicing, DNA damage
and repair, nuclear transport, and others [92].
Lysine acetylation has been reported in various neurodegenerative
disorders, including ALS [93-96]. For example, misfolded tau protein
acetylation serves as a disease marker for Alzheimer’s pathology [96].
Similarly, TDP-43 acetylation impairs RNA-binding and promotes cytoplasmic
aggregation that resembles the TDP-43 pathology in ALS patients [94].
Furthermore, in a yeast study, human FUS was overexpressed, resulting in
decreased acetylation of histone H3, specifically on lysine 14 (H3K14) and
lysine 56 (H3K56) [97]. Additionally, these cells showed overall low RNA levels
suggesting that FUS proteinopathy might be related to decreased
transcription.
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In addition, FUS has also been found to interact with histone
deacetylase 1 (HDAC1) in neurons [98]. This interaction is important for the
recruitment of HDAC1 to DNA double strand break sites in response to DNA
damage. Another study found that FUS ΔNLS/ΔNLS knock-in mice showed
HDAC1 mislocalization to the cytoplasm, suggesting that FUS cellular
localization affects the function of its interacting partners [98].
1.2.8 Conclusion and study rationale
In summary, FUS is ubiquitously expressed in the cells and different
studies have described its functions in the nucleus and the cytoplasm. On the
other hand, we also know that lysine acetylation is one of the major PTMs that
can regulate several functions in the cells. There is evidence by several studies
that FUS can be modified by arginine methylation regulating the nuclear import
of FUS, and FUS phase separation [99-101]. However, acetylation of FUS is
yet to be reported and represents an understudied mechanism in ALS and
FTLD-FUS pathology. In this study we asked whether FUS is modified by
acetylation, what sites can be acetylated in FUS, and what are the functional
consequences of FUS acetylation. The goal of this study is to find new
regulators of the function of FUS that provide more information on the
molecular disease mechanism, and to characterize novel targets for
therapeutic approaches in ALS and other neurodegenerative disorders.
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1.3

Materials and Methods

1.3.1 Cell culture and transfection
HEK293Tand N2A cells were cultured in Dulbecco’s Modified Eagle’s
Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum, penicillinstreptomycin, and amphotericin B at 37°C in 5% CO2/95% air with
humidification. The pCMV10-3×FLAG-FUS WT and pEGFP-C3 FUS plasmids
were generated as reported [83] FUS mutations were introduced using the
QuikChange II Site-Directed Mutagenesis Kit (Agilent). HEK293T and N2A
cells were transfected with Polyethylenimine “Max” (Polysciences, Inc. 24765)
and Lipofectamine 2000 (Thermo Fisher Scientific, 11668), respectively.
1.3.2 Immunoprecipitation (IP)
Cells were lysed with 1× RIPA buffer (Millipore Sigma, 20-188)
supplemented with protease inhibitor cocktail (Millipore Sigma, P8340, 1:500),
sodium orthovanadate (1 mM), and deacetylase inhibitor (DACi) cocktail
(nicotinamide (20 mM), sodium butyrate (20 mM) and Trichostatin-A (1.5 µM)).
Lysates were homogenized by sonication and centrifuged at 1,000g for 15
minutes at 4°C. Immunoprecipitations were performed overnight at 4°C using
EZview™ Red ANTI-FLAG® M2 Affinity Gel (Millipore Sigma, F2426) or
4µg/ml mouse monoclonal ANTI-FLAG® M2 antibody (Millipore Sigma,
F3165) and Protein G UltraLink Resin (Thermo Fisher Scientific, 53126).
Beads were washed three times with lysis buffer and bound proteins were
eluted with 0.15 µg/µL 3×FLAG peptide (Millipore Sigma, F4799) in 1× RIPA
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buffer at 4°C for 1 hour. Samples were resolved by SDS-PAGE followed by
immunoblotting. Where indicated, a cocktail of RNase A and RNase T1 (Life
Technologies, AM2286) was added to the lysates at 1:100 dilution before the
overnight immunoprecipitation.
1.3.3 Immunoblotting
Proteins resolved by SDS-PAGE were transferred to nitrocellulose
membranes (Pall, 66485). The membranes were blocked with 5% non-fat dry
milk in TBST (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.1% Tween-20) or bovine
serum albumin (BSA) for 1 hour. The antibodies used include: mouse antiFUS (Santa Cruz, sc-47711), mouse monoclonal ANTI-FLAG® M2Peroxidase (HRP) (Millipore Sigma, A8592), rabbit anti-acetylated-lysine (Cell
Signaling Technology, 9441), rabbit anti-PABP1 (Abcam, ab21060), mouse
anti- β -actin (Santa Cruz Biotechnology, sc-81178), rabbit anti-β-actin (Cell
Signaling 8457), and a custom-made rabbit anti-K510-acetylated FUS
antibody (see below).
1.3.4 Identification of FUS acetylation by Mass Spectrometry
FLAG-tagged FUS was transfected into HEK293T cells. Transfected
cells were treated overnight with a cocktail of lysine deacetylase inhibitors (30
mM nicotinamide, 50 mM sodium butyrate and 3 µM Trichostatin-A) one day
post-transfection in regular medium. Anti-FLAG immunoprecipitation was
performed immediately after deacetylase inhibitor treatment. Eluates were run
on SDS-PAGE and the gel was stained with SYPRO Ruby protein gel stain
16

(Thermo Fisher Scientific, S12000). The bands that corresponded to FLAGFUS (electrophoretic mobility of approx. 72 kDa) were excised and subjected
to dithiothreitol reduction, iodoacetamide alkylation, and in-gel chymotrypsin
digestion. Peptides were extracted, concentrated and subjected to LC-MS/MS
analysis at the University of Kentucky Proteomics Core Facility as previously
reported (48). Briefly, LC-MS/MS analysis was performed using an LTQOrbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled
with an Eksigent Nanoflex cHiPLC™ system (Eksigent , Dublin, CA) through
a nano-electrospray ionization source. The peptide samples were separated
with a reversed phase cHiPLC column (75 μm x 150 mm) at a flow rate of 300
nL/min. Mobile phase A was water with 0.1% (v/v) formic acid while B was
acetonitrile with 0.1% (v/v) formic acid. The data-dependent acquisition
method consisted of an Orbitrap MS scan (300-1800 m/z) with 60,000
resolution for parent ions followed by MS/MS for fragmentation of the 7 most
intense multiple charged ions. The LC-MS/MS data were submitted to a local
MASCOT server for MS/MS protein identification via Proteome Discoverer
(version 1.3, Thermo Fisher Scientific, Waltham, MA) against a custom
database

containing

only

RNA-binding

protein

FUS

(FUS_HUMAN)

downloaded from Uniprot. Typical parameters used in the MASCOT MS/MS
ion searchinclude: chymotrypsin digestion with a maximum of three missed
cleavages; 10 ppm precursor ion and 1.2 Da fragment ion mass tolerances;
lysine acetylation; cysteine carbamidomethylation; methionine oxidation.

17

1.3.5 Generation of FUS KO (∆FUS) N2A cells.
The FUS knockout cells were generated by employing CRISPR
technology. N2A cells were transfected with FUS double nickase CRISPR
plasmid

(Santa

Cruz

Biotechnology,

sc-433326-NIC)

following

the

manufacturer’s instructions. Clonal cell lines were isolated with serial dilution,
and the FUS status of the clones was determined with immunoblotting.
1.3.6 Generation of the anti-acetylated-K510 FUS antibody.
All peptides below were synthesized with an added extra N-terminal
cysteine residue to facilitate conjugation to Sulfolink resin or KLH (Genscript,
Piscataway, NJ). The rabbit anti-acetylated-K510 FUS antibody was raised
against the peptide antigen N-G504GFGPG(K510Ac)MDSRG515-C. The
peptide was synthesized with C-terminal amidation and conjugated to Keyhole
Limpet Hemocyanin (KLH) for immunization (Pocono Rabbit Farm and
Laboratory, Canadensis, PA). The serum was first depleted with the nonacetylated FUS peptide N-G504GFGPGK510MDSRGEHRQDRRERPY526C,

then

affinity-purified

with

the

acetylated

G504GFGPG(K510Ac)MDSRGEHRQDRRERPY526-C

FUS

peptide

conjugated

Nto

Sulfolink resin (Thermo Fisher Scientific, 44999). The antibodies were eluted
with 0.1 M glycine-HCl buffer, pH 2.5, neutralized by the addition of Tris-HCl,
1 M, pH 8.5, and dialyzed against storage buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 10% glycerol, 0.04% [w/v] sodium azide).
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1.3.7 GST-TNPO1 purification
The human TNPO1 coding region was PCR amplified with primers 5’CGTCGGATCCATGGAGTATGAGTGGAAACCT-3’

and

5’-

CGTCGTCGACTTAAACACCATAAAAAGCTGCAAGA-3’ from MGC clone
4178989 as template and inserted between the BamHI and SalI sites of pGEX6P-3 (GE Healthcare 28-9546-51). The GST-TNPO1 fusion protein was
expressed in Rosetta 2 (DE3) pLysS E. coli cells (Millipore 71401) at 28°C
incubation temperature, purified using Glutathione Sepharose 4B resin (GE
Life Sciences, 17-0756-01) following the manufacturer’s recommendations,
and eluted with 15 mM reduced L-glutathione (Gold Biotechnology, G-155-25)
in 100 mM Tris-HCl, pH 8.0, and 2 mM DTT. Aliquots were flash-frozen in liquid
nitrogen and stored at −80°C until use.
1.3.8 GST-TNPO1 pulldown with Sulfolink-immobilized FUS peptides
The acetylated and non-acetylated FUS peptides synthesized with an
added extra N-terminal cysteine residue were immobilized to Sulfolink resin
following the manufacturer’s instructions (Thermo Fisher Scientific, 44999).
The beads were blocked with 0.5mg/mL BSA in TNPO1 buffer (20mM NaPO4, pH7.4, 150mM KCl, 0.5mM EDTA, 5mM MgCl2, 10% glycerol, 1mM
DTT, 20mM Nicotinamide) for 1h at 4°C. The indicated amounts of GSTTNPO1 were added to the blocked beads with the immobilized FUS peptides
and incubated at 4°C for 3 hours with mild rotation. The beads were washed
with TNPO1 buffer 3 times and eluted by the addition of 2× Laemmli sample
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buffer with beta-mercaptoethanol. After incubation at 94°C for 5 minutes, the
eluted samples were subjected to SDS-PAGE and Western blot.
1.3.9 Immunoprecipitation followed by qPCR
Immunoprecipitation was carried out as described above, with the
difference that SUPERase-In RNase Inhibitor (Thermo Fisher Scientific,
AM2696, 0.2 U/µl) was added to the lysis and elution buffers, and incubation
with the antibody was performed for 2 hours. In the last step of the
immunoprecipitation, the eluted sample was divided into two aliquots. One
aliquot was used for immunoblotting and the other was used for RNA isolation
using TRIzol Reagent (Thermo Fisher Scientific, 15596), following the
manufacturer’s instructions. Equal aliquots of the isolated RNA were reverse
transcribed using the SuperScript III First-Strand Synthesis System (Thermo
Fisher Scientific, 18080). The resulting cDNA was subjected to quantitative
real-time PCR using Power SYBR Green PCR Master Mix (Thermo Fisher
Scientific, 4367659). The qPCR primers and annealing temperatures were:
mouse FUS pre-mRNA flanking exon 7, 5’-CAACCCTTTTGTAGCCGTTGG3’ and 5’-CAGCAGGAGGCATTCTACCC-3’, 59°C; and mouse RPL13A, 5’CTGTGAAGGCATCAACATTTCTG-3’

and

5’-

GACCACCATCCGCTTTTTCTT-3’ [102], 55°C. The qPCR results were
analyzed using the ∆∆CT method.
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1.3.10 Immunofluorescence and fluorescence microscopy
N2A cells were seeded on gelatin-treated coverglass and transfected
with EGFP-FUS constructs. Cells were treated with the lysine deacetylase
inhibitor cocktail for six hours when indicated. 48h after transfection, cells were
fixed with 4% formaldehyde in 1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4, pH 7.4), and permeabilized with 1× PBS
supplemented with 0.25% [v/v] Triton-X100. The coverslips were blocked with
10% [w/v] BSA in 1× PBS for 1h, followed by incubation with primary antibody
at room temperature overnight. Coverslips were rinsed with 1× PBS and
incubated with secondary antibodies for 1 hour at 37°C. The primary antibody
was rabbit anti-G3BP1 (Proteintech, 13057-2-AP) and the secondary antibody
was Alexa Fluor 568 donkey anti-rabbit (Thermo Fisher Scientific, A10042). All
the samples were stained with 4′,6-Diamidino-2-phenylindole (DAPI) and
mounted with Vectashield Mounting Medium (Vector Laboratories, H-100010). Confocal images were acquired using a Nikon A1 confocal microscope
with a 40x objective. Z-stack images were obtained from random view fields
using identical parameters for all the samples. Maximum intensity projections
of the Z-stacks were analyzed using ImageJ (http://imagej.nih.gov/ij) as
reported previously [103]. Inclusion-positive cells were defined as any cell with
one or more inclusions larger than 5 pixels. The number of inclusion-positive
cells was normalized with the total number of GFP-positive cells in each view
field.
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1.3.11 Patient skin fibroblast isolation and culture
Human skin fibroblasts were prepared and maintained as described
(78). ALS patients and healthy family members consented to donate the
samples. Protocol was reviewed and approved by the Institutional Review
Board of the University of Kentucky. A skin biopsy of 3 mm diameter was
obtained from the subjects and the tissue was washed in phosphate-buffered
saline (PBS), minced, and incubated in Minimum Essential Medum (SigmaAldrich, M5650) supplemented with 20% FBS, 2 mM L-glutamine, 100 unit/mL
penicillin, and 100 μg/mL streptomycin) at 37°C under 5%CO2/95% air.
Information on the subjects examined in this study is shown in Table 1.1
1.3.12 Statistical analysis
The quantification of Western blot bands was performed using Image
Lab software by BioRad. Statistical analysis was performed with SigmaPlot
14.0 software. Band intensities were calculated and comparison between
groups was performed using Anova with post hoc Tuckey HSD test. Student’s
t test was used to determine statistical significance between two groups. Chi
square was used to compare difference between proportions. Experiments
were not blinded. Fluorescence microscopy was quantified from more than 10
different view fields and all experiments were done in triplicates.
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Table 1.1. List of patient fibroblast
ID

Group

FUS
genotype

Gender

017

Control

WT/WT

Female

Age of
sample
collection
43

010

Control

WT/WT

Female

36

012

Control

WT/WT

Female

63

008

Control

WT/WT

Female

24

089

Control

WT/WT

Male

20

091

ALS patient

WT/R521G

Female

31

014

ALS patient

WT/R521G

Male

42

007

ALS patient

WT/R521G

Male

58

018

ALS patient

WT/R521G

Female

40

090

ALS patient

WT/P525R

Female

26
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1.4

Results

1.4.1 FUS is acetylated at specific lysine residues in two distinct functional
domains.

To evaluate whether FUS was acetylated, we immunoprecipitated
endogenous FUS from N2A cells treated with a deacetylase inhibitor (DACi)
cocktail (30 mM nicotinamide, 50 mM sodium butyrate and 3 µM TrichostatinA), followed by immunobloting with a pan-acetylated lysine antibody. A
prominent acetylated FUS band was observed in the presence of DACi cocktail
as compared to a significantly weaker band in the absence of DACi (Figure
1.2A). The result suggests that FUS is acetylated and the acetylation is
dynamic.
Next, we used LC-MS/MS to identify the lysine acetylation sites.
3×FLAG-tagged FUS was transfected into HEK293T cells and treated with the
DACi cocktail overnight. Subsequently, a FLAG immunoprecipitation (FLAGIP) was performed, and the eluates were run on SDS-PAGE followed by
SYPRO Ruby staining. FUS bands at approximately 72 kDa were excised,
subjected to in-gel chymotrypsin digestion, and analyzed by liquid
chromatography tandem mass spectrometry (LC-MS/MS) as previously
described [104]. Figure 1.2B shows the mass spectrometric evidence of FUS
acetylation at K510 and Figure 1.2C shows the di-acetylation at K315 and
K316.
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We next validated these three acetylation sites using a mutagenesis
approach, in which acetylation mimicking mutants (Lys to Gln or K/Q) were
generated for each site. Mutating lysine to glutamine is a method widely used
in the field to study protein acetylation [94, 104] In our data, replacing lysine
with glutamine at K315 or K316 alone did not result in significant loss of FUS
acetylation (Figure 1.2D-E). However, when these two sites were mutated
together, FUS acetylation was decreased significantly (Figure 1.2D-G). This
suggests that acetylation at both sites may occur interchangeably, which is
consistent with the detection of di-acetylation of K315 and K316 in the LCMS/MS analysis. Similarly, K510Q mutant decreased FUS acetylation
significantly, and mutating the three sites also showed acetylation decrease
(Figure 1.2F-G). FUS lysine acetylation was not completely abrogated in the
triple K315/316/510Q mutant, suggesting that additional acetylation sites
might be present beyond the detection limit in our study.
Lysine residues 315 and 316 are localized in the RNA recognition motif
(RRM), specifically in the very positively charged KK-loop that facilitates the
electrostatic interaction between FUS and DNA/RNA (Figure 1.2H). NMR
structure of the RRM domain found that K315 and K316 are inserted into the
major groove of the stem-loop RNA and in contact with the ribose-phosphate
backbone of both strands [105]. Previous studies have shown that replacing
lysine residues by alanine in the KK-loop disrupted nucleic acid binding [57].
Thus, we hypothesized that acetylation of K315/K316 could regulate the RNA
binding of FUS by a similar mechanism (Figure 1.2I). In contrast, lysine 510 is
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localized in the C-terminal NLS (Figure 1.2J). The NLS of FUS interacts with
the nuclear transport receptor Transportin-1 (TNPO1) at multiple positively
charged residues including K510, and this interaction is crucial for nuclear
localization and function of FUS [81, 85]. Our hypothesis was that acetylation
at K510 disrupts the interaction between FUS and D693 of TNPO1 (Figure
1.2J) by removing the positive charge of lysine and imposing steric hindrance.
The net effect was predicted to be that K510 acetylation affects the interaction
with TNPO1 and thereby regulates the subcellular localization of FUS.

1.4.2 Acetylation of FUS at K315/K316 regulates its RNA binding activity.

To test the hypothesis that acetylation of K315/K316 regulates RNA
binding to FUS, we first tested FUS binding to its own pre-mRNA surrounding
exon 7 as previously reported [72]. The 3×FLAG-tagged FUS (WT and K-Q
acetylation mimicking mutants) was immunoprecipitated and the quantity of
FUS pre-mRNA was measured by reverse transcription and quantitative PCR.
The K315/316Q acetylation mimicking mutant co-precipitated significantly less
FUS mRNA as compared to WT FUS (Figure 1.3A). In contrast, K510Q did
not change the RNA binding. As a control, we verified that the total FUS premRNA levels were comparable in all cell extracts (Figure 1.3A).
A second assay was used to test FUS RNA binding by examining the
interaction between FUS and poly-A binding protein (PABP1), which was
reported to be RNA-dependent [83]. We performed a FLAG-IP from N2A cells
26

transfected with 3×FLAG-tagged WT or K/Q mutant FUS to examine the FUSPABP1 interaction. As expected, in the presence of RNase cocktail containing
a mixture of RNAse A and RNASe T1, the WT FUS-PABP1 interaction was
completely abrogated (Figure 1.3B-C). When the cells were treated with DACi
cocktail, the WT FUS-PABP1 interaction decreased significantly, suggesting
that acetylation affected RNA binding. We also found that the PABP1-FUS
interaction was affected even by single K/Q mutations in the KK-loop, and
when both sites were mutated to glutamine, the interaction was impaired at
similar levels as the DACi treatment itself (Figure 1.3B-C). In contrast, K510Q
mutant did not affect the FUS-PABP1 interaction. Overall, these results
support the hypothesis that lysine acetylation of K315/K316 impairs FUS
binding to RNA.

1.4.3 The effect of FUS K510 acetylation on the FUS NLS-TNPO1 interaction.

To test the hypothesis that acetylation of K510 affects the interaction
between FUS and TNPO1 and influences the subcellular localization of FUS,
we employed chemically synthesized FUS-NLS containing the acetylated
K510 in an in vitro interaction study with TNPO1. The acetylated and nonacetylated FUS-NLS peptides were immobilized to Sulfolink resin and
incubated with different amounts of purified GST-TNPO1. The pulldown of
TNPO1 by the non-acetylated FUS peptide was detectable with the lowest
amount of 12.5 pmol TNPO1 (Figure 1.3D). However, the K510-acetylated
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FUS-NLS peptide pulled down significantly less TNPO1 noting that the
interaction was almost undetectable with 25 pmol of TNPO1 (Figure 1.3D-E).
As a control, Sulfolink beads without FUS peptide were subjected to the same
immobilization protocol and incubated with 0 or 200 pmol of TNPO1. No signal
was detected at 0 pmol of TNPO1 but a weak band was detected when 200
pmol of TNPO1 was incubated with the blank beads. Thus, acetylation of K510
affected the interaction between FUS and TNPO1, suggesting that this posttranslational modification in the NLS reduces the nuclear import of FUS and
hence may alter cytoplasmic localization.

1.4.4 Acetylation of FUS at distinct sites differentially alter cellular localization and
stress granule formation.

Since the acetylation at K315/K316 and K510 residues affects the FUSRNA and the FUS-TNPO1 interaction, respectively, we used acetylation mimic
K/Q mutants to determine whether acetylation of these lysine residues
differentially affect its subcellular localization and inclusion formation by
fluorescence microscopy. In Figure 1.4A, EGFP-tagged WT FUS was
localized to the nuclei of N2A cells. Similarly, the K315Q/K316Q mutant was
localized to the nuclei of the cells, suggesting that acetylation of K315/K316
residues did not affect FUS nuclear localization. In contrast, ~30% of the
K510Q mutant showed cytoplasmic localization while ~40% of the triple K/Q
mutant FUS was in the cytoplasm (Figure 1.4A-B). More interestingly, ~59%
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of cells expressing the K510Q mutant FUS showed cytoplasmic inclusions
whereas

only

~22%

of

cells

expressing

the

triple

mutant

K315Q/K316Q/K510Q showed cytoplasmic inclusions (Figure 1.4C, p<0.001).
The reduced formation of cytoplasmic inclusions by the triple K/Q mutant
suggests that that RNA binding is important for the formation of FUS
cytoplasmic inclusions, which is consistent with our previous report [106].
Next, we assessed whether the cytoplasmic inclusions formed by acetylation
mimicking mutants were colocalized with the stress granule marker G3BP1 in
N2A cells using fluorescence microscopy. As expected, EGFP-FUS WT and
K315Q/316Q neither formed inclusions nor co-localized with G3BP1. In
contrast,

EGFP-FUS

K510Q

and

K315Q/K316Q/K510Q

cytoplasmic

inclusions were co-localized with G3BP1 (Figure 1.5). These results are
consistent with previous studies that ALS mutant FUS forms cytoplasmic
inclusions co-localized with stress granule markers [83, 86]. Taken together,
we conclude that the acetylation of K510 affects the interaction between FUS
and TNPO1, causing the mis-localization of FUS to the cytoplasm and the
formation of stress granule-like inclusions. In addition, the acetylation of
K315/K316 reduces the RNA binding and suppresses FUS-positive stress
granules.

29

1.4.5 FUS acetylation in the RRM domain decreases the formation of ALS mutant
inclusions.

To further test whether acetylation of K315/K316 in the KK-loop of the
RRM domain affects the formation of FUS cytoplasmic inclusions by disrupting
RNA binding, we transfected N2A cells with the EGFP-tagged FUS ALS
mutant P525L with or without harboring the acetylation mimicking mutation
K315Q/K316Q. The P525L mutation itself caused mis-localization to the
cytoplasm as previously reported [107] and ~48% of the P525L mutantexpressing cells showed cytoplasmic inclusions (Figure 1.4D-E). However,
only ~11% of cells expressing the P525L/K315Q/K316Q mutant FUS showed
cytoplasmic

inclusions (Figure

1.4D-E,

p<0.001).

Furthermore,

cells

expressing EGFP-P525L FUS were treated with the DACi cocktail and the
percentage of cells with cytoplasmic inclusions decreased from ~33% in the
absence of DACi to ~5% in the presence of DACi (Figure 1.4F-G, p<0.001).
Thus, the results support that the acetylation of the K315/K316 residues
reduces the ability of ALS mutants of FUS to form cytoplasmic inclusions

1.4.6 K510 acetylation is increased in FUS ALS patients

Since the K510 acetylation mimicking mutant significantly increased
cytoplasmic mis-localization and inclusion formation (Figure 1.4A-C), we
examined the status of K510 acetylation in ALS patients. We first generated a
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site-specific antibody against acetylated K510. The rabbit polyclonal antibody
specifically detected hyper-acetylated FUS in human HEK293T cells and
mouse N2A cells in the presence of DACi, but did not detect any signal in FUSnull N2A cells (Figure 1.6A). Additionally, we transfected FUS-null N2A cells
with either empty vector, or WT, K510Q, or K510R FUS with or without DACi
cocktail. The antibody detected a strong band in extracts from WT FUSexpressing cells treated with DACi, whereas it did not detect any signal in
K510R mutant extract treated with DACi (Figure 1.6B). The acetylation
mimicking mutant K510Q produced a very faint band, thus, the antibody is
specific for FUS acetylation of K510. We used this acetyl-K510 specific
antibody to analyze human skin fibroblast samples from FUS ALS patients and
healthy controls. Levels of K510 acetylation were normalized against total
FUS. We found ∼50% increased levels of acetylated FUS K510 in ALS

patients (p = 0.015) (Figure 1.7A-B). These results suggest that acetylation of
FUS could be associated with pathological characteristics of FUS ALS.

1.4.7 FUS is acetylated by CBP/p300
The CREB-binding protein (CBP) and p300 form a select family of lysine
acetyltransferases (KATs) due to their structural and functional similarities
[108, 109]. These proteins are responsible for a large portion of the acetylation
of histone and non-histone proteins in mammalian cells [109]. FUS has been
shown to interact with CBP/p300 [39], and to verify that CBP/p300 acetylates
FUS we co-transfected HA-tagged CBP and FLAG-tagged FUS into N2A cells.
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After FLAG immunoprecipitation, pan-acetylated lysine antibody showed a
strong signal when HA-CBP was present compared to HA-empty vector
(Figure 1.8A), indicating that FUS was acetylated by CBP/p300.
We then treated N2A cells with DACi cocktail plus compound A-485, a
highly selective CBP/p300 inhibitor [110], at different concentrations for 24h.
We detected a significant signal decrease in acetylated-K510 FUS with
increasing concentrations of A-485 (Figure 1.8B-C). Interestingly, treatment of
8 µM A-485 did not change the total acetylation as detected by the panacetylated lysine antibody while K510 acetylation significantly decreased
(Figure 1.8D). The results suggest that endogenous CBP/p300 is a major
acetyltransferase at the K510 site of FUS.

1.4.8 FUS is deacetylated by HDAC and Sirtuins lysine deacetylases
Lysine deacetylases are enzymes that play an important role in
regulating epigenetic changes that are critical for gene expression. They are
classified into different families: HDACs are Zn2+-dependent lysine
deacetylases while Sirtuins require nicotinamide adenine dinucleotide (NAD+)
[111]. To identify which family of lysine deacetylases deacetylate FUS, we
treated N2A cells with two deacetylase inhibitors for 24h: nicotinamide which
inhibits sirtuins [112], and Trichostatin-A (TSA) which inhibits a broad range of
HDACs

[113]. We

first

examined

the

total

acetylation

by

FLAG

immunoprecipitation followed by Western blot using a pan-acetylated lysine
antibody (Figure 1.8E-F). Cells treated with nicotinamide showed a trend of
32

increase without statistical significance. Cells treated with TSA showed a
significant increase of total FUS acetylation. Cells with both nicotinamide and
TSA showed ~8x increase of total FUS acetylation as compared to the control
(Figure 1.8E-F). Next, we evaluated the effect of these inhibitors on the K510
site. In cells treated with nicotinamide or TSA alone, we observed a significant
increase in FUS-K510 acetylation compared to the vehicle control. In the same
fashion, treating with both nicotinamide and TSA together, we detected a ~15x
increase in FUS-K510 acetylation (Figure 1.8G-H). This suggests that both
HDACs and Sirtuins are able to deacetylate FUS.
We next used co-precipitation assays to identify candidate FUS lysine
deacetylases. A set of FLAG-tagged expression constructs for all known
human lysine deacetylases (HDACs 1-11 and SIRTs 1-7) were transfected into
HEK293T cells, followed by endogenous FUS immunoprecipitation. Among
the 11 HDACs and 7 SIRTs (Figure 1.9A-B) tested, only HDAC3 and SIRT7
co-precipitated with the endogenous FUS (Figure 1.8I), suggesting that these
lysine deacetylases might be involved in FUS deacetylation. SIRT6 and
hnRNPA1 were included as a negative and positive control in the coprecipitation study, respectively (Figure 1.8I). The results in Figure 1.8I are
consistent with the results in Figure 1.8E-H that the FUS acetylation level
increased in the presence of either HDAC or SIRT inhibitors.
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1.5

Discussion
FUS is a DNA/RNA binding protein that belongs to the FET/TET family
of proteins, including TAF15 and EWS. FUS mutations have been linked to
familial ALS [29] and FUS pathology is also found in a subset of FTD [114].
FUS is a ubiquitously expressed protein that has many molecular functions in
the cell. In this study, we found that the biochemical properties of FUS are
modulated by acetylation. First, using a mass spectrometry approach, we
identified lysine acetylation sites in the RRM domain and C-terminal NLS of
FUS. Lysine residues 315 and 316 are located in the KK-loop, which is a
structural component of the RRM domain and is involved directly in DNA and
RNA binding [57]. The lysine residue 510 is located in the NLS of FUS, a
domain that is primarily responsible for importing FUS into the nucleus.
Remarkably, mutations in this site (K510E, K510R and K510M) have been
reported in familial ALS cases [115-117]. These findings led us to hypothesize
that acetylation of lysine at these sites could influence the biochemical function
of FUS in the cell.
FUS-NLS domain harbors most of the reported ALS mutations,
resulting in aberrant FUS protein mis-localization and aggregation in the
cytoplasm [82-85]. The interaction between FUS-NLS and TNPO1 is critical
for importing FUS into the nucleus. Structural analysis showed that the
positively charged K510 residue interacts with the negatively charged D693
residue of TNPO1 (Figure 1.2J) [81]. It is conceivable that the addition of an
acetyl group to K510 could disrupt the interaction between K510 and D693. In
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addition, the acetyl group can also cause steric hindrance between the K510
and D693 residues. Thus, K510 acetylation would reduce FUS binding affinity
to TNPO1 and increase the cytoplasmic localization of FUS. It was reported
that familial ALS patients with the K510R mutation manifest a mild phenotype
and long survival after disease onset [117]. Although both arginine and lysine
contain positively charged side chains, the Arg side chain is spatially larger
than Lys, consistent with the notion that the K510R mutation may disrupt the
FUS NLS-TNPO1 interaction to a lesser degree, accounting for mild disease
phenotypes. In contrast, FUS K510E ALS patients showed early onset and
rapid progression of the disease supporting the concept that a negative charge
at position 510 is particularly deleterious [118]. Our previous data showed that
K510E has only 1% binding affinity to TNPO1 [81], and it has been shown that
a severe disruption of nuclear import could be correlated with a rapid
progression of the disease [119]. These results suggest that FUS NLS is
sensitive to perturbations at the K510 residue, including mutations or posttranslational modifications like acetylation discovered in this study. Indeed, our
results showed that FUS acetylation at K510 disrupted the interaction with
TNPO1 (Figure 1.3D-E), leading to the cytoplasmic accumulation of FUS and
the formation of G3BP1-positive stress granule-like inclusions in the cytoplasm
(Figure 1.4A-C, Figure 1.5). Several transgenic mice models have shown that
cytoplasmic

aggregation

neurodegeneration

and

[120-122],

inclusion
supporting

hypothesis.
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FUS-RRM domain has been reported to bind various nucleic acids,
ranging from DNA to G-quadruplex RNA [57]. The K315/K316 motif in FUSRRM domain exhibits tandem positive charges at the protruding tip of the KK
loop and contributes significantly to the electrostatic interaction with the
negatively charged nucleic acids. Point mutations K315A/K316A abolished
FUS nucleic acid binding [57]. Similarly, our results show that acetylation
mimicking mutations in the KK-loop significantly reduce the RNA binding
capability of FUS (Figure 1.3A-C), most likely by neutralizing the positive
charge of lysine, leading to a decreased affinity to the negatively charged
backbone of the nucleic acids [123]. Finally, the attachment of an acetyl group
to lysine could cause a steric clash with its interaction partners.
An interesting observation from our immunofluorescence experiments
was that transfecting the cells with EGFP-K315Q/K316Q/K510Q caused FUS
to mis-localize to the cytoplasm, but the percentage of cells with cytoplasmic
inclusions decreased significantly when compared to EGFP-K510Q (Figure
1.4C). These results are in agreement with our previous study that FUS-RNA
binding is required for the formation of cytoplasmic inclusions [86]. That study
demonstrated that when FUS RNA binding domains were truncated, the
formation of inclusions significantly decreased as compared to the R495X FUS
ALS mutant. Other work showed that mutating K315 and K316 to Ala residues
prevented the formation of cytoplasmic inclusions by the R495X mutant [57].
These data are consistent with the results obtained in this study that
introducing the acetylation mimics at the RNA-binding sites into the ALS
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mutant P525L (P525L/K315Q/K316Q) significantly reduced the percentage of
cells with cytoplasmic inclusions as compared to the P525L mutation alone
(Figure 1.4D-E). Consistent with these findings, we showed that treating cells
expressing the P525L ALS mutant with deacetylase inhibitor cocktail
significantly reduced the percentage of cells with cytoplasmic inclusions
(Figure1.4F-G). Our results are relevant to a recent study showing that
dynamic multi-valent interaction between FUS and RNA is critical to
maintaining the fluidity and function of FUS [124].

FUS mutations that

constrain the FUS-RNA interactions lead to higher order complex of
ribonucleoprotein aggregates [124]. Finally, RNA binding was also shown to
play a critical role in the formation of stress granules and pathological inclusion
of TDP-43 [125]. These studies support our conclusion that RNA binding is
critical for self-assembly of FUS into cytoplasmic inclusions and that Lys
acetylation in the RRM domain can effectively modulate RNA binding and
inclusion formation of mutant FUS.
To identify the lysine deacetylases that might regulate FUS acetylation,
we first used nicotinamide and TSA to test whether FUS acetylation is
susceptible to Sirtuins or HDACs, respectively. Our results showed that total
FUS acetylation as well as FUS K510 acetylation can be mediated by both
Sirtuins and HDACs (Figure 1.8E-H). It is noted that the effect of nicotinamide
alone on the total acetylation level was not statistically significant. It has been
reported that the expected inhibitory effect of nicotinamide could be unreliable,
in particular, nicotinamide was reported to stimulate the SIRT1 activity [126].
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We next examined which specific Sirtuin or HDAC interacted with FUS using
immunoprecipitation. We found that SIRT7 and HDAC3 interact with FUS. The
FUS-SIRT7 interaction was previously reported in a proteomics study [127] but
was not experimentally validated. SIRT7 is a NAD+-dependent deacetylase
that acts on histone and non-histone proteins [128] and it is localized in the
nucleus, but primarily in the nucleolus [129]. Moreover, we identified a novel
interaction between HDAC3 and FUS. HDAC3 is a Zn2+-dependent class-I
HDAC that has been reported to shuttle between the nucleus and the
cytoplasm [130]. An interaction between FUS and HDAC1 was reported
previously [38], however we could not confirm this interaction under our
experimental conditions. Future studies of genetically reducing HDAC3 and
SIRT7 are needed to confirm that they indeed deacetylate FUS.
We also demonstrated that endogenous CBP/p300 is a major
acetyltransferase for FUS, particularly the K510 site (Figure 1.8A-D). The
CBP/p300 inhibitor A-485 [110] significantly decreased FUS K510 acetylation
in a dose-dependent manner in N2A cells (Figure 1.8B-C), however the total
FUS acetylation did not show significant change, suggesting that the
acetylation of the specific K510 site is more sensitive to CBP/p300 inhibitor.
Reports show that CBP/p300 is localized to the nucleus [131] and is
responsible for acetylation of over two-thirds of the lysine acetylation sites.
Overall, the process of FUS acetylation/deacetylation appears to be very
dynamic, and it is likely that other acetyltransferase enzymes play a role in
FUS acetylation at other sites such as K315/K316. The functional
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consequence of inhibiting the specific acetyltransferases (e.g. CBP/p300) and
deacetylases (e.g. SIRT7 and HDAC3) on the subcellular localization and
inclusion formation of FUS remains to be determined in future studies.
To our knowledge, lysine acetylation of human FUS has not been
reported previously. A proteomics study reported the acetylation of K502 in rat
FUS and K640 in rat EWS, the equivalent of K510 in human FUS. The
acetylation of the K263 residue in rat TAF15 was also reported, which
corresponds to K316 in human FUS [132]. Although the acetylation of those
residues was not further validated and their functional relevance was not
studied, the proteomic identification of acetylation of these conserved residues
in the FET family proteins across species is supportive of the importance of
our findings demonstrating acetylation of K315, K316 and K510 residues. Our
mutagenesis and pharmacological studies demonstrate that acetylation of
these residues bestowed a profound impact on FUS subcellular localization as
well as the formation of stress granule-like cytoplasmic inclusions.
More interestingly, a higher K510 acetylation level was observed in
familial FUS ALS patients as compared to healthy controls (Figure 1.7A-B),
suggesting that acetylation could play a role in disease pathogenesis and/or
serve as a molecular hallmark of the disease. Particularly, K510 acetylation
increased the cytoplasmic inclusions (Figure 1.4A-C). Based on all results in
this study, a working model is proposed to illustrate the role of FUS acetylation
(Figure 1.10). Acetylation of K315/K316 disrupts the RNA binding but does not
interfere with the TNPO1-mediated nuclear import of FUS. In contrast,
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acetylation of K510 disrupts the interaction with TNPO1 and promotes the
formation of cytoplasmic inclusions. When all three lysine residues are
acetylated, FUS accumulates in the cytoplasm but forms less inclusions due
to impaired RNA binding. We propose this process to be dynamic and the three
forms of FUS acetylation can be present simultaneously. For ALS-linked
mutations, mutant FUS shows reduced TNPO1 binding, impaired nuclear
import, and cytoplasmic accumulation. Moreover, mutant FUS shows a higher
level of K510 acetylation in ALS patients, facilitating the formation of
cytoplasmic inclusions. Future studies are needed to test whether CBP/p300
inhibitors can mitigate mutant FUS mediated disease pathology by
suppressing the K510 acetylation.
The pathologic inclusions are a clinical characteristic of mutant FUS
mediated ALS/FTD. Studies show that different types of stress granules can
form in a G3BP1-dependent [133] or independent [134] fashion, and can
generate different functional outcomes [135]. The role of acetylation of FUS in
stress granules and the functional consequence of such acetylationdependent granules remains to be determined in future studies. In addition, a
recent study reported that nuclear-to-cytoplasmic mis-localization of FUS
without aggregation in the cytoplasm occurred in different models of FUS ALS
[136]. We propose that pharmacologically modulating acetylation of FUS can
prevent protein mis-localization or formation of pathological inclusions,
providing new targets for therapeutic treatments against FUS-mediated
ALS/FTD and other neurodegenerative diseases.
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Figure 1.1 The functional domains of FUS

QGSY-rich, Glutamine/Glycine/Serine/Tyrosine rich domain; G, Glycine
rich domain; RGG, Arginine/Glycine/Glycine rich domain; E, Nuclear export
signal; RRM, RNA recognition motif; ZnF, Zinc finger domain; NLS, Nuclear
Localization Signal
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Figure 1.2 FUS is acetylated
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(A) Endogenous FUS immunoprecipitation from N2A cells treated with
deacetylase inhibitor cocktail (DACi) (nicotinamide (30 mM), sodium butyrate
(50 mM) and Trichostatin-A (3 µM)) for 6h. Immunoblotting was performed
using the indicated antibodies. (B) Mass spectrometric identification of the
acetylated

FUS

peptide

RGGRGGGDRGGFGPGK510MDSRGEHRQDRRERPY.
spectrum

of

the

(C)

di-acetylated

305FKQIGIIKTNKKTGQPMINLYTDRETGKL333.

The

MS/MS
peptide

The series of matched b and y

ions are shown in blue and red, respectively. The b11, b12, y18 and y19 ions
supporting the K315 and K316 acetylation sites are labeled in bold. (D)
3×FLAG-tagged WT, K315, K316Q, K315Q/K316Q or FLAG vector control
were transfected into N2A cells. After 24h, cells were treated with deacetylase
inhibitor cocktail for 6h, followed by FLAG immunoprecipitation and
immunoblotting with the indicated antibodies. (E) Quantification of FUS
acetylation from three independent experiments ± SD. Student’s t-test was
performed for individual comparisons against WT. *, p ≤0.05. (F) 3×FLAGtagged WT, K315Q/K316Q, K510Q, K315Q/K316Q/K510Q or FLAG vector
control were transfected into HEK293T cells. After 24h, cells were treated with
deacetylase inhibitor cocktail for 6h, followed by FLAG immunoprecipitation
and immunoblotting with the indicated antibodies. (G) Quantification of FUS
acetylation from three independent experiments ± SD. Student’s t-test was
performed for individual comparisons against WT. *, p ≤0.05. (H) The domain
structure of FUS showing the RRM domain sequence and acetylation sites. (I)
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NMR solution structure of FUS RRM domain (pink) showing K315 and K316
in the KK-loop bound to stem-loop RNA (Protein Data Bank entry 6GBM). (J)
Crystal structure of TNPO1/FUS-NLS (Protein Data Bank entry 4FQ3)
illustrating the FUS-NLS domain (pink) K510 adjacent to TNPO1 (purple)
D693. I-J were generated using the UCSF ChimeraX software.
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Figure 1.3. Acetylation of FUS impairs RNA binding and the FUS NLS-TNPO1
interaction

(A) 3×FLAG-tagged FUS constructs were transfected into N2A cells.
After 48h, cells were lysed, and FLAG-IP followed by reverse transcription and
quantitative PCR against FUS pre-mRNA surrounding exon 7 was performed.
FUS mRNA was normalized with the FLAG levels in the FLAG-FUS
immunoprecipitations and with the Rpl13a mRNA levels in the total extracts.
Averages of three independent experiments are shown, ± SD. Student’s t-test
was performed for individual comparisons against WT. (B) The indicated
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3×FLAG-tagged FUS constructs were transfected into N2A cells and treated
with DACi cocktail where indicated. FLAG immunoprecipitation was performed
48h after transfection with the inclusion of RNase cocktail as indicated,
followed by immunoblotting with the indicated antibodies. (C) Quantification of
(B) from three independent experiments. Student’s t-test was performed for
individual comparisons against WT. Significance: *, p ≤0.05; **, p≤0.005; ***,
p ≤0.001; n.s: not significant. (D) In vitro TNPO1 pulldown with Sulfolinkimmobilized acetylated or non-acetylated FUS-NLS peptides. Different
amounts of GST-TNPO1 were incubated with FUS-NLS peptide immobilized
on the beads at 4°C for 3 hours. The amount of TNPO1 pulled down with FUSNLS peptides were evaluated by Western blot. (E) Quantification of (D) from
three independent experiments, ± SD. Student’s t-test was performed
comparing the band intensities of non-acetylated and acetylated peptide
pulldowns at the same concentration. Significance: *, p ≤0.05; **, p≤0.005; ***,
p≤0.001; n.s: not significant
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Figure 1.4. The effect of FUS acetylation on cellular localization and stress
granule formation.

(A) N2A cells were transfected with EGFP-tagged WT, K315Q/K316Q,
K510Q and K315Q/K316Q/K510Q FUS. The nuclei were visualized with DAPI.
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Samples were examined by confocal microscopy. Scale bars, 10µm. (B)
Quantification of nuclear and cytoplasmic EGFP-tagged FUS intensity ± SD
(n>200 cells) using ImageJ scripts. One Way Anova was performed to
determine statistical significance. *p ≤0.05; **p≤0.005; ***p≤0.001; n.s: not
significant. (C) The percentage of EGFP-positive cells with cytoplasmic
inclusions (n > 100 cells). * p ≤0.001. (D) N2A cells were transfected with
EGFP-tagged WT, P525L, and P525L/K315Q/K316Q FUS. The nuclei were
visualized with DAPI. Samples were examined by confocal microscopy. Scale
bars, 10µm. (E) The percentage of EGFP-positive cells with cytoplasmic
inclusions (n > 100 cells). * p ≤0.001. (F) N2A cells were transfected with
EGFP-tagged WT or P525L FUS. One set of P525L transfected cells were
treated with deacetylase inhibitor (DACi) cocktail (30 mM nicotinamide, 50 mM
sodium butyrate and 3 µM Trichostatin-A). The nuclei were visualized with
DAPI. Samples were examined by confocal microscopy. Scale bars, 10µm.
(G) The percentage of EGFP-positive cells with cytoplasmic inclusions (n >
100 cells). * p ≤0.001.
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Figure 1.5. FUS acetylation mimicking mutant inclusions co-localize with the
stress granule marker G3BP1.

Co-localization of endogenous G3BP1 with EGFP-tagged FUS in N2A
cells. The co-localization of FUS and G3BP1 is shown by arrows. Scale bars,
10µm.
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Figure 1.6. Characterization of the anti-K510-acetylated FUS antibody.

(A) HEK293T, N2A, and N2A-∆FUS (FUS knockout) cells were treated
with deacetylase inhibitor (DACi) cocktail (30 mM nicotinamide, 50 mM sodium
butyrate and 3 µM Trichostatin-A), as indicated.

Immunoblotting was

performed using the indicated antibodies. (B) N2A ∆FUS cells were
transfected with 3×FLAG-tagged WT, K510R, or K510Q FUS or vector control
with or without DACi cocktail as indicated. Immunoblotting was performed
using the indicated antibodies.
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Figure 1.7. K510 acetylation is increased in familiar FUS ALS.
(A) FUS-K510 acetylation levels in ALS patients with R521G or P525R
FUS mutations versus control subjects. Immunoblotting was performed using
the indicated antibodies. (B) Quantification of FUS-K510 acetylation
normalized against total FUS levels. Error bars represent SD between
individuals. One Way Anova was performed to determine statistical
significance. *, p ≤ 0.05.
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Figure 1.8. The regulators of FUS acetylation

(A) 3×FLAG-FUS or 3×FLAG-vector was co-transfected with HA-CBP
or HA-vector into N2A cells. FLAG immunoprecipitation was performed,
followed by immunoblotting using the indicated antibodies. (B) N2A cells were
treated with different concentrations of the CBP/p300 inhibitor A-485 in the
presence of DACi cocktail. Immunoblotting was performed using the indicated
antibodies (C) Quantification of (B), from three independent experiments ± SD.
Student’s t-test was performed for individual comparisons against no
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treatment. *p ≤0.05. (D) N2A cells were transfected with FLAG-vector or
FLAG-FUS and treated with CBP/p300 inhibitor A-485 (8µM) for 16h in the
presence of DACi cocktail.

FLAG immunoprecipitation was performed,

followed by immunoblotting with the indicated antibodies. (E) N2A cells were
transfected with FLAG-FUS and treated with 30 mM nicotinamide and/or 3 µM
Trichostatin-A for 6h. FLAG immunoprecipitation was performed followed by
immunoblotting with the indicated antibodies. (F) Quantification of (E), from
three independent experiments ± SD. (0µM). *p ≤0.05. One-way Anova was
performed to determine statistical significance. *, p ≤0.05; **, p≤0.005; (G) N2A
cells were treated with 30 mM nicotinamide and/or 3 µM Trichostatin-A for 6h.
Cells were harvested and lysed after treatment and immunoblotting was
performed using the indicated antibodies. (H) Quantification of (G), from three
independent experiments ± SD. One-way Anova was performed to determine
statistical significance. *, p ≤0.05; **, p≤0.005; ***, p≤0.001; n.s,: not significant.
(I) HEK293T cells were transfected with 3×FLAG-empty vector, 3×FLAGSIRTs 6-7, 3×FLAG-HDAC3, and 3×FLAG-ROA1 (hnRNPA1) used as a
positive control. After 48h, endogenous FUS immunoprecipitation was
performed, followed by immunoblotting using the indicated antibodies.
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Figure 1.9. Interaction screening of FUS with lysine deacetylases.

(A) HEK293T cells were transfected with 3×FLAG-HDAC 1-11 (A) or
3×FLAG SIRT 1-7 (B). After 48hrs, endogenous FUS immunoprecipitation was
performed, followed by immunoblotting using the indicated antibodies. The
3×FLAG-ROA1 (hnRNPA1) construct was used as a positive control.
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Figure 1.10. Proposed model of the role of FUS acetylation in the modulation of
FUS subcellular localization and inclusion formation

Acetylation of K315/K316 disrupts the RNA binding but does not
interfere with the TNPO1-mediated nuclear import of FUS. In contrast,
acetylation of K510 disrupts the interaction with TNPO1 and promotes the
formation of cytoplasmic inclusions. When all three lysine residues are
acetylated, FUS accumulates in the cytoplasm but forms less inclusions due
to impaired RNA binding. We propose this process to be dynamic and the three
forms of FUS acetylation can be present simultaneously. For ALS-linked
mutations, mutant FUS shows reduced TNPO1 binding, impaired nuclear
import, and cytoplasmic accumulation.
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CHAPTER 2. FUS REGULATES THE TRANSCRIPTION OF GENES CRITICAL
TO AUTOPHAGY
2.1

Abstract
FUS/TLS (Fused in Sarcoma/Translocated in Liposarcoma) is a
ubiquitously expressed RNA-binding protein that has been reported to play
different roles in the cell. Mutations in FUS have been linked to a subset of
familial cases of the neurodegenerative disease amyotrophic lateral sclerosis
(ALS). FUS is mainly localized in the nucleus, although it shuttles between the
nucleus and the cytoplasm to transport RNAs, and it is also present in the
cytoplasm of neuronal cells. [29]. Mutations in the nuclear localization
sequence (NLS) of FUS, causes its mis-localization to the cytoplasm where it
forms inclusions that co-localize with stress granule proteins. Stress granules
are dynamic complexes that are form by proteins, ribosomes and RNAs, and
they can be degraded by the autophagy pathway. It has been shown that
stress granules containing mutant FUS co-localize with autophagosomes,
however the role of FUS in this pathway needs to be elucidated. In this study
we found that KO FUS cells had a decreased basal autophagy flux. Treatment
with Bafilomycin A1 and rapamycin showed that KO FUS cells were not able
to induce autophagy as efficiently as WT cells, suggesting that the initial
phases of the autophagy pathway are affected in FUS KO cells. We found that
FIP200, ATG16L1, and ATG12 mRNA and protein levels were significantly
lower in FUS KO cells. Overexpressing FUS in FUS KO cells was able to
rescue gene and protein expression levels of FIP200 and ATG16L1. Our
findings demonstrate a novel role of FUS in the autophagy pathway, by
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regulating the transcription of genes involved in the initial stages of autophagy,
such as initiation and phagophore elongation.

2.2

Introduction

2.2.1 FUS in cytoplasmic inclusions and stress granules dynamics

Many of the familial ALS-related FUS mutations are localized in the Cterminal NLS, causing mis-localization of FUS to the cytoplasm where it forms
inclusions that co-localize with stress granule proteins [82-85]. Cytoplasmic
aggregates are a hallmark of neurodegenerative diseases, with neurofibrillary
tangles (NFTs) in Alzheimer's disease (AD) [137], Lewi bodies in Parkinson’s
disease (PD), or inclusion bodies in ALS tissue samples [138]. In fact, all
sporadic and familial non-SOD1 ALS patients, display FUS inclusions in the
spinal cord. These inclusions are also immunoreactive to TDP43, p62, and
ubiquitin [139].
Moreover, protein aggregation can be induced after cellular stress
[140]. Stress granules are dynamic membrane-less cytoplasmic complexes of
proteins, ribosomes, and RNAs that form under oxidative stress, hyperosmolar
stress, or heat shock [141]. The precise role of stress granules remains to be
fully understood, however it has been suggested that they can serve as
storage sites for further mRNA translation or degradation [142]. Several
studies have reported that mutant FUS inclusions, co-localized with stress
granules markers [82, 83, 143-145]. A study showed that cells expressing
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ALS-linked FUS mutations form cytoplasmic inclusions that co-localize with
stress-granule proteins such as PABP1, TIA-1, G3BP1 [83, 146]. However,
FUS is not required for stress granule assembly [145]. The previous evidence
shows that FUS is involved in stress granule dynamics, and that alterations in
this process by FUS mutations can lead to aberrant aggregation with other
RNA-binding proteins and RNAs. Protein turn-over pathways, particularly
autophagy, help clear pathogenic aggregates from the cells and maintain
protein homeostasis.

2.2.2 Autophagy pathway

There are two major protein degradation pathways: the ubiquitinproteasome system (UPS) and the autophagy pathway. The UPS is
responsible for the degradation of short-lived soluble proteins, while the
autophagy pathway can degrade misfolded proteins and whole organelles
[147] (The autophagy pathway is illustrated in Figure 2.1).
mTOR is a well-known regulator of autophagy that acts as an inhibitor
of the pathway when the cells are under nutrient-rich conditions, by preventing
the formation of the autophagy initiation complex (ULK1-ATG13-FIP200).
When starvation conditions hit the cells, or cells are treated with rapamycin,
mTOR is inhibited and autophagy starts with activation of the initiation complex
and formation of the phagophore [148].
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Subsequently, elongation of the phagophore is facilitated by two
ubiquitin-like systems: ATG12:ATG5:ATG16L system and PE-LC3 system.
These two processes are governed by ATG (AuTophaGy-related proteins).
The first complex receives autophagy initiation signals, and localizes to the
autophagy isolation membrane for elongation [149]. A sequence of events that
resemble the ubiquitin-proteasome pathway are involved in this step. First,
Atg12 binds Atg5 through an E1-like enzyme Atg7. Then, Atg12-Atg5
conjugates with Atg16L1 through the reaction with E2-like enzyme Atg10
[149], resulting in the ATG12:ATG5:ATG16L system.
Similarly, PE-Atg8 system is in charge of Atg8 processing. Atg8 (LC3)
is synthesized with an extra C-terminus sequence that is removed by Atg4.
This process helps to expose the glycine residue of Atg8 (LC3-I), that is
required for the next steps of the reaction. Then, Atg7 and Atg3 activate Atg8,
in order to attach phosphatidylethanolamine (PE) to the Atg8-C-terminal
glycine (LC3-II). PE is necessary for the attachment of this protein to the
phagophore membrane. Finally, Atg12-Atg5-Atg16L1 and Atg8-PE function
synergistically to promote autophagosome elongation [150].
When the phagophore elongates and encloses the targeted misfolded
proteins,

or

damaged

organelles,

it

forms

a

double-membraned

autophagosome [151]. Afterwards, Atg12-Atg5-Atg16L disassembles from the
membrane, but LC3-II remains attached in the autophagosome membrane
until the latest steps of the pathway. Thus, LC3-II is a good marker to evaluate
autophagy flux [152].
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Finally, the mature autophagosome fuses with the lysosome, and its
contents are degraded by acidic proteases. Subsequently, the amino acids
and other by-products of the degradation are recycled back into the cytoplasm,
where they can be re-used for cell metabolism [153].

2.2.3 Autophagy and ALS

Neurons are post-mitotic cells that are highly susceptible to protein
aggregation, thus defects in protein homeostasis are particularly detrimental
for neurons. The balance between protein folding, assembly and degradation
is necessary for the normal function of the cells [154] This balance is
maintained by several factors, including proteolytic machinery and protein
chaperones [155, 156].
Defects

in

the

autophagy

pathway

have

been

reported

in

neurodegenerative diseases such Alzheimer’s disease and ALS [157-159]. A
pathological characteristic of ALS is the accumulation of insoluble protein
aggregates in the cytoplasm of motor neurons [154]. Under normal conditions,
when protein aggregates form, cells have quality control mechanisms to
degrade misfolded proteins, to prevent protein aggregation, or to clean up
aggregates that have already formed [147]. However, under pathological
conditions, cytoplasmic aggregates result from misfolded proteins that lose
their native conformations and fail to be cleared from the cell by the ubiquitinproteasome pathway or autophagy [147]. The common phenotype of protein
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aggregation in neurodegenerative diseases suggests that the mechanisms to
maintain protein homeostasis are disrupted and that cytoplasmic aggregates
become aberrant and might contribute to cytotoxicity [147].
Some studies have found evidence that autophagy dysregulation might
be associated to ALS. For instance, a study analyzed post-mortem samples
from sporadic ALS patients and found that cytoplasmic inclusions in motor
neurons were immunoreactive to p62 and LC3-II [160]. In another study, p62positive inclusions were found in iPSCs derived from patients with C9orf72
expansion [161]. Interestingly, when autophagy was inhibited by chloroquine
treatment, cell viability decreased in these cells. In another study involving
iPSCs derived from ALS/FTLD patients with C9orf72 haploinsufficiency, LC3II autophagy flux as significantly reduced [162]. Together, these studies
suggest that autophagy is essential for maintaining protein homeostasis in
neuronal cells.
In a performed in SOD1 G93A mice, an autophagy inducer lithium was
found to delay the disease onset and increase the life span. The
neuroprotective effects were coupled with the autophagy activation and a
larger number of mitochondria in motor neurons [163]. Interestingly, a pilot
study in 44 ALS patients with no placebo-controls showed that patients treated
with lithium carbonate survived until the end of the study while 29% of patients
treated with riluzole died by the same time [163]. These results suggest that
autophagy induction might provide a protective effect for neurodegeneration.
However, a multicentre, randomised, double-blind, placebo-controlled clinical
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trial found that, although there were no safety concerns, there was no evidence
of benefit of lithium on survival in patients with ALS (cite: Lancet Neurol. 2013
Apr; 12(4): 339–345.). Thus, the clinical efficacy of the autophagy inducer
lithium in ALS remains unclear.
A study showed that autophagy deficient mouse embryonic fibroblasts
(MEFs) showed an increase in mutant FUS-positive stress granules. In
addition, stress granules that contain mutant FUS co-localize with
autophagosomes [157]. Furthermore, induction of autophagy by rapamycin
treatment in mutants FUS cells, reduced stress granule formation and cell
death in neurons [157] . These results suggest that the autophagy pathway is
important for clearance of mutant FUS cytoplasmic inclusions. In another
study, post-mortem tissue from sporadic adult-onset ALS showed basophilic
inclusions that were immunoreactive for p62, LC3, and FUS [164]. A recent
study showed that mutant FUS disrupts autophagy by affecting the formation
of the omegasome [165], a membrane derived from the ER, and sites where
phagophores form [166]. Together, these studies indicate that autophagy is an
important mechanism involved in neurodegeneration, and dysregulation of this
pathway may cause negative effects in motor neurons, leading to diseases
such as ALS.
2.2.4 Study rationale

In summary, neurodegenerative diseases are characterized for toxic
protein aggregation in the cytoplasm of neuronal cells. Since these are post62

mitotic cells that do not undergo cell division, they are susceptible to defects
in protein homeostasis. A few studies have shown a connection between FUS
and the autophagy pathway. However, the specific function of FUS in this
pathway remain to be studied. Here, we asked whether mutant FUS disrupts
autophagy flux, and whether loss of FUS affects the expression of proteins
involved in various stages of autophagy.

2.3

Materials and Methods

2.3.1 Cell culture and transfection
N2A, FUS KO N2A, and NSC34 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum, penicillinstreptomycin, and amphotericin B at 37°C in 5% CO2/95% air with humidification. The
pCMV10-3×FLAG-FUS plasmids, were generated as reported [83]. Cells were treated
with bafilomycin A1 (200nM) for 6 hours, Rapamycin (2µM) for 4h, or MG-132 (5µM)
for 16 hours. FUS mutations were introduced using the QuickChange II Site-Directed
Mutagenesis Kit (Agilent). N2A, FUS KO N2A and NSC34 cells were transfected with
Lipofectamine 2000 (Thermo Fisher Scientific, 11668). siRNA-FUS (Santa Cruz, sc40563) oligonucleotides were reversed-transfected into N2A and NSC34 cells at a
final concentration of 1µM using Lipofectamine™ RNAiMAX (Thermo Fisher
Scientific, 13778100).
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2.3.2 Generation of FUS KO (∆FUS) N2A cells.
The FUS knockout cells were generated by employing CRISPR
technology. N2A cells were transfected with FUS double nickase CRISPR
plasmid

(Santa

Cruz

Biotechnology,

sc-433326-NIC)

following

the

manufacturer’s instructions. Clonal cell lines were isolated with serial dilution,
and the FUS status of the clones was determined with immunoblotting.

2.3.3 Generation of the FLAG-FUS knock-in cells lines
FLAG-tagged FUS WT was transfected into FUS KO N2A cells using
Lipofectamine 2000 as described above. Selection of stable cells with FLAGFUS WT integration was performed with G-418 (Millipore Sigma G418-RO).
Clonal cells lines were isolated with serial dilution, and the FUS expression
levels were compared to endogenous FUS in N2A cells by western blot, using
anti-FUS and anti-FLAG antibodies.

2.3.4 Western blot analysis
Cells were lysed with 1x RIPA buffer (Millipore Sigma, 20-188)
supplemented with protease inhibitor cocktail (Millipore Sigma, P8340, 1:500)
and sodium orthovanadate (1 mM). Lysates were homogenized by sonication
and centrifuged at 1,000g for 15 minutes at 4°C. Supernatant was collected
and protein concentration was determined using a colorimetric Protein Assay
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Dye Reagent Concentrate (BIO-RAD, 5000006,). 6x SDS buffer sample was
added to samples containing equal amounts of protein and heated for 5 min at
95ºC. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose
membranes (Pall, 66485). The membranes were blocked with 5% non-fat dry
milk in TBST (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, 0.1% Tween-20) or bovine
serum albumin (BSA) for 1 hour.
2.3.5 Antibodies
The antibodies used include mouse anti-FUS (Santa Cruz, sc-47711),
mouse monoclonal ANTI-FLAG® M2-Peroxidase (HRP) (Millipore Sigma,
A8592), rabbit anti-β-actin (Cell Signaling 8457). LC3 (Millipore Sigma L8918),
Mouse anti-SQSTM-p62 (H00008878-M01), Autophagy Induction (ULK1
Complex) Antibody Sampler Kit (Cell Signaling 46486,) containing ULK1
(D8H5) Rabbit mAb (Cat #8054), Atg13 (D4P1K) Rabbit mAb (Cat# 13273),
FIP200 (D10D11) Rabbit mAb (Cat#12436), Atg101 (E1Z4W) Rabbit mAb
(Cat#13492), Phospho-ULK1 (Ser757) (D7O6U) Rabbit mAb (Cat#14202),
Phospho-ULK1 (Ser555) (D1H4) Rabbit mAb (Cat#5869). Autophagy
Antibody Sampler Kit (Cell Signaling, 4445) containing Beclin-1 (D40C5)
Rabbit mAb (Cat#3495), Atg5 (D5F5U) Rabbit mAb (Cat#12994), Atg12
(D88H11) Rabbit mAb (Cat#4180), Atg16L1 (D6D5) Rabbit mAb (Cat#8089),
Atg7 (D12B11) Rabbit mAb (Cat#8558), Atg3 Antibody (Cat#3415).
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2.3.6 TaqMan qPCR Assay
RNA isolation was performed using Aurum Total RNA Mini Kit (BIORAD, 732-6820) following the manufacturer’s instructions. 1µg of isolated RNA
was reverse transcribed using the SuperScript III First-Strand Synthesis
System (Thermo Fisher Scientific, 18080). The resulting cDNA was subjected
to Real-time PCR. Briefly, FAM-labeled Taqman probes for autophagy related
genes and controls were obtained from the TaqMan Gene expression assay
library from ThermoFisher Scientific. TaqMan® Fast Advanced Master Mix
(ThermoFisher Scientific, 4444556, Thermo Fisher Scientific) was prepared
following manufacturer’s instructions. The assay IDs for the FAM-labelled
probes analyzed are: Mm00456545_m1 (Rbcc1, FIP200), Mm00509659_m1
(Atg101),

Mm00512209_m1

(Atg7),

Mm00471287_m1

(Atg3),

Mm00503201_m1 (Atg12), Mm00513085_m1 (Atg16L1), Mm01612987_g1
(Rpl13a), Mm99999915_g1 (GAPDH), Mm00607939_s1 (Actin). The qPCR
results were analyzed using the ∆∆CT method.

2.3.7 Statistical analysis
Lane quantification for Western blot bands was performed using Image
Lab software by BioRad. Statistical analysis was calculated with SigmaPlot
14.0 software. Band intensities were calculated and comparison between
groups was performed using Anova with post hoc Tuckey HSD test. Student’s
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t test was used to determine statistical significance between two groups.
Experiments were not blinded. All experiments were done in triplicates.

2.4

Results

2.4.1 ALS-linked mutant FUS did not affect autophagy
First, we tested whether the ALS-linked FUS mutations would affect the
levels of basal autophagy. FUS KO N2A cells were transfected with FLAGtagged WT, R495X, R521G, or P515L FUS. The levels of autophagy markers
LC3-I, LC3-II, and p62 were subsequently analyzed by Western blot. To our
surprise, the LC3-II/LC3-I ratios and the p62 level did not change between any
mutant FUS as compared to WT FUS (Figure 2.2 A-B), indicating that mutant
FUS did not affect the autophagy flux.
2.4.2 FUS knockout reduced the basal level of autophagy
We next examined whether the absence of FUS would affect the
autophagy pathway. We used siRNA to knockdown FUS and evaluated the
levels of autophagy markers LC3-I and LC3-II. The LC3-II/LC3-I ratio was
reduced in the FUS knockdown cells as compared to WT cells (Figure 2.3A).
We tested the LC3-I and LC3-II levels in FUS KO N2A cells and obtained a
similar result that the LC3-II/LC3-I ratio decreased in the FUS KO cells (Figure
2.3B). Together, these data suggest that FUS might be an important player
during autophagy initiation, phagophore elongation, or autophagy flux.
To test whether FUS plays a role in the autophagy initiation,
phagophore elongation, or autophagy flux stage, we treated N2A and N2A
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FUS KO cells with bafilomycin A1 or rapamycin, followed by Western blots of
autophagy markers. Bafilomycin A1 disrupts the late stages of the autophagy
flux by inhibiting the autophagosome-lysosome fusion and preventing
autolysosome acidification [167]. Consistent with earlier results, the ratio of
LC3-II/LC3-I was significantly lower in FUS KO cells as compared to WT cells
without Bafilomycin A1 (Figure 2.3C-D). After the Bafilomycin A1 treatment
(200 nM, 6 hrs), the LC3-II/LC3-I ratio increased significantly in WT N2A cells
(Figure 2.3C, lane 2 vs lane 1) as well as FUS KO cells (Figure 2.3C, lane 4
vs lane 3). However, even in the presence of Bafilomycin A1, the LC3-II/LC3I ratio was still significantly lower in FUS KO cells compared to WT cells (Figure
2.3C, lane 4 vs lane 2). These results suggest that FUS KO did not affect the
late stages of autophagosome-lysosome fusion or autophagy flux, but rather
affected the early stages of the autophagy pathway.
Rapamycin is a well-stablished mTOR inhibitor that induces the
initiation of autophagy [168]. After the Rapamycin treatment (2 µM, 4 hrs), the
LC3-II/LC3-I ratio significantly increased in WT N2A cells as compared to nontreatment (Figure 2.3E-F, lane 2 vs lane 1). In contrast, the LC3-II/LC3-I ratio
did not change in FUS KO cells in the presence of rapamycin (Figure 2.3E-F,
lane 4 vs lane 3), suggesting that FUS KO cells were not able to respond to
the rapamycin-mediated initiation of autophagy.
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2.4.3 FUS affected the levels of proteins critical in early phases of autophagy
We next analyzed the expression of proteins involved in the ULK1
initiation complex that is composed of ULK1, Atg13, Atg101 and FIP200. This
complex promotes or suppresses the autophagy process depending on the
nutrient status of the cell [169]. We tested the expression of Atg13, Atg101,
FIP200, total ULK1 and phosphorylated ULK1 in WT and FUS KO N2A cells
(Figure 2.4A-B). Atg13, Atg101, total ULK1 expression did not change
between WT and FUS KO cells. The phosphorylation on UKL1 Ser757 or
Ser555 did not change in FUS KO cells either (Figure 2.4C). Interestingly,
FIP200 expression was significantly reduced in FUS KO cells as compared to
WT cells (Figure 2.4A-B).
We also evaluated the proteins involved in the phagophore elongation
[150]: Atg3, Atg5, Atg12, Atg7 and Atg16L1 (Figure 2.4D-E). Atg3, Atg16L1,
and the Atg5-Atg12 complex showed a significant decrease in FUS KO cells
as compared to WT cells. However, the protein level of Atg5 alone did not
change between FUS KO and WT cells, indicating that only Atg12 protein was
affected in the absence of FUS. Similarly, Atg7 did not change in FUS KO
cells. Taken together, these results suggest that FUS likely plays an important
role in the autophagy initiation and phagophore elongation stages by
regulating the expression of FIP200, Atg3, Atg12 and Atg16L1.
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2.4.4 FUS regulated the transcription of genes involved in early phases of
autophagy
Since FUS regulated the protein levels, we examined whether FUS
might regulated the transcription of corresponding genes involved in the initial
phases of autophagy using quantitative RT-PCR. For genes involved in the
autophagy initiation, the mRNA levels of FIP200 showed a significant
decrease (~57%) in FUS KO cells (Figure 2.4F) while Atg101 and Atg7 mRNA
levels did not significantly change between the two groups. For genes involved
in the phagophore elongation, the mRNA levels of Atg3 (~48%), ATG16L1
(~54%), and Atg12 (~48%) decreased significantly in FUS KO cells (Figure
2.4G). Atg7 was used as a negative control and did not change significantly.
These results suggest that FUS likely plays a role in regulating the gene
expression of those critical to the autophagy initiation and phagophore
elongation.

2.4.5 FUS knock-in restores expression of autophagy related genes.
To further solidify our conclusion, we examined whether reexpression of FUS in the FUS KO cells can restore the expression of the
affected autophagy related genes. To this end, we generated a cell line that
stably expresses FLAG-tagged WT FUS in N2A-FUS KO cells, hereby named
FUS knock-in (KI) cells. The expression level of FUS in the FUS KI cells was
comparable in WT N2A cells. FUS KI significantly restored the protein levels
of Atg16L1 (100%) and FIP200 (~80%) as compared to FUS KO cells (Figure
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2.5A-B). Similarly, FUS KI also increased the mRNA levels of Atg16L1 and
FIP200 as compared to the FUS KO cells (Figure 2.5C). The mRNA levels of
Atg16L1 and FIP200 were restored to ~60% in WT N2A cells. The results
support that FUS plays a role in regulating the transcription of the genes
involved in the autophagy initiation and phagophore elongation.

2.5

Discussion
FUS is a DNA/RNA binding protein that has been linked to familial
cases of ALS , and its pathology has been reported in FTD patients [114].
Research has found that FUS plays multiple roles in various pathways inside
the cell. We hereby report a previously unknown function of FUS, i.e. FUS
regulates the initiation of autophagy by mediating the transcription of genes
that are critical to autophagosome formation.
We found that the expression of mutant FUS did not change the levels
of autophagy markers (Figure 2.2). The role of autophagy in FUS mediated
ALS has been debated. One study reported that impairment of the proteasome
pathway replicated ALS phenotypes in mice with TDP-43 and FUS
proteinopathy, but impairment of the autophagy pathway by motor neuronspecific knock-out of Atg7 did not show ALS phenotype [170]. However,
another study showed that torkinib, an autophagy-enhancing compound that
functions as an mTOR inhibitor, reduced FUS cytoplasmic aggregates and
rescued motor function in P525L iPSC-derived motor neurons [171]. Thus, it
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remains possible that both UPS and autophagy pathways contribute to the
degradation of toxic protein aggregates in various experimental systems in
neurodegenerative diseases [172].
Our results showed that overexpression of mutant FUS did not affect
autophagy in N2A cells, which is supported by a study showing that the
expression of FUS mutant R521C did not impair autophagy [157]. However,
another study reported that overexpressing mutant FUS impairs autophagy by
disrupting early stages of Rab-1 dependent autophagy pathway [173]. It is
possible that mutant FUS affected the autophagy pathway differently in
different experimental systems.
More interestingly, FUS knockdown or knockout cells showed
significantly decreased levels of autophagy flux marker (Figure 2.3A-B).
Moreover, the FUS knockout cells did not respond to rapamycin treatment as
WT cells did (Figure 2.3E-F). Consistently, the level of LC3-II increased in the
presence of Bafilomycin A1, but the level in FUS knockout cells was
significantly lower than that in WT cells (Figure 2.3C-D). The results suggest
that FUS is involved in the LC3-II lipidation, phagophore elongation and
autophagosome formation.
Furthermore, we demonstrated that the mRNA and protein levels of
FIP200, Atg3, Atg16L1 and Atg12 decreased in FUS KO cells (Figure 2.4),
which were restored by expression of FUS (Figure 2.5). ULK1, FIP200 and
Atg13 form a complex that is required for ULK1 localization to the isolation
membrane and subsequent phagophore formation [174-176]. Atg101 is
72

associated with the ULK1 complex by interacting with Atg13 [177]. Among the
four genes/proteins examined, only FIP200 was affected by FUS KO. FIP200
has been reported to be an essential regulator of autophagy in Drosophila
melanogaster [178] and mammalian cells [179]. In both studies, when the
FIP200 was silenced, the induction of autophagy activity was severely
impacted. Thus, we conclude that the regulation of FIP200 expression by FUS
is a critical mechanism in autophagy initiation.
Atg (AuTophaGy-related) genes function as a ubiquitin-like conjugation
system to facilitate LC3-II lipidation and phagophore elongation [150]. Among
five Atg genes examined in this study, the levels of Atg3, Atg16L1 and Atg5Atg12 complex decreased consistently. The Atg5-Atg12 complex conjugates
with Atg16L1 [180] and facilitate the attachment of phosphatidylethanolamine
(PE) to the C-terminal glycine of Atg8 (LC3) [149], which promotes phagophore
elongation [150, 181, 182]. These studies support our model (Figure 2.6) that
FUS regulates the expression of genes critical to LC3 lipidation, phagophore
elongation, and autophagosome formation.
It is noted that it is yet to be determined in future studies how FUS
regulates the expression of FIP200, Atg3, Atg16L1 and Atg12 genes. FUS was
reported to be associated with active chromatin [48], to interact with nuclear
receptors [61], transcription factors [60], and RNA polymerase II and the TFIID
complex [44], suggesting that FUS is part of the transcription machinery.
However, it is unclear how FUS specifically regulate these genes while it does
not change other Atg genes. It is conceivable that there are specific elements
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in the regulatory region of these genes that specifically interact with FUS.
Future studies are needed to determine such FUS-interacting elements for
those genes.
Our study discovered a novel function of FUS in protein homeostasis.
Specifically, FUS regulates the early stages of autophagy by modulating the
transcription of genes that play a role in autophagy initiation (FIP200) and
phagophore elongation (Atg12 and Atg16L1). The lack of FUS causes the
downregulation of the gene expression and protein levels, leading to
decreased phagophore formation, and thus the reduction in basal autophagy
flux (Figure 2.6). The function of FUS in autophagy in vivo remains to be further
examined in future studies. The significance of FUS regulation of autophagy
genes in the context of neurodegenerative diseases such as ALS and FTD is
also to be better understood.
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Figure 2.1. The autophagy pathway.

mTORC is a negative regulator of autophagy. Under normal conditions
mTORC inhibits autophagy, however under starvation or after rapamycin
treatment, mTORC is inhibited and autophagy starts. The ULK initiation
complex starts downstream signaling for the generation of the phagophore.
Then, the phagophore elongates by the action of Atg12:Atg5:Atg16L and PEAtg8 conjugation system. The phagophore encloses the cargo that needs to
be degraded forming a mature autophagosome that fuses with a lysosome.
The lysosome releases acidic proteases that degrade the cargo. Finally, the
degraded contents are recycled back to the cell for further metabolism.
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Figure 2.2 Mutant FUS does not affect basal autophagy

(A) FUS knockout N2A cells were transfected with FLAG-tagged
vector, WT FUS, FUS-R495X, R521G, P525L. 48h after transfection cells
were collected and immunoblotting was performed with the indicated
antibodies. (B) Quantification of (A) from three independent experiments ± SD.
Student’s t-test was performed for individual comparisons against FLAG-FUS
WT. *, p ≤0.05.
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Figure 2.3 Basal autophagy is affected in FUS KO cells

(A) N2A cells were transfected with FUS siRNA using Lipofectamine™
RNAiMAX. 48h after transfection cells were harvested and immunoblotting
was performed using the indicated antibodies. (B) N2A and FUS knockout
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(KO) N2A cells were cultured and immunoblotting was performed using the
indicated antibodies. (C) N2A and KO cells were treated with Bafilomycin A1
(200 nM) for 6h. Cells were harvested, and immunoblotting was performed
with the indicated antibodies. (D) Quantification of (C) from three independent
experiments ± SD. One Way Anova was performed to determine statistical
significance. *p ≤0.05; **p≤0.005. (E) N2A and KO cells were treated with
Rapamycin (2µM) for 4h. Cells were harvested, and immunoblotting was
performed with the indicated antibodies. (F) Quantification of (E) from three
independent experiments ± SD. One Way Anova was performed to determine
statistical significance. *p ≤0.05; **p≤0.005.
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Figure 2.4. FUS regulates transcription of genes involved in autophagy initiation
and phagophore elongation

79

(A) N2A and FUS knockout (KO) N2A cells were cultured and
immunoblotting was performed using the indicated antibodies. (B-C)
Quantification of (A) from three independent experiments ± SD. Student’s ttest was performed for individual comparisons against N2A WT cells. *, p
≤0.05. (D) N2A and KO cells were cultured, and immunoblotting was
performed using the indicated antibodies. (E) Quantification of (D) from three
independent experiments ± SD. Student’s t-test was performed for individual
comparisons against WT N2A WT cells. *, p ≤0.05. (F-G). N2A and KO cells
were cultured and harvested for RNA isolation, followed by reverse
transcription and quantitative PCR using TaqMan probes for the indicated
genes. Actin was used to normalize the protein expression. Averages of three
independent experiments are shown, ± SD. Student’s t-test was performed for
individual comparisons against N2A WT cells.
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Figure 2.5. FUS knock-in restores expression of autophagy related genes.

(A) N2A, FUS knockout (KO), and FUS knock-in (KO + WT) cells were
cultured, and immunoblotting was performed using the indicated antibodies.
(B) Quantification of (A) from three independent experiments ± SD. One Way
Anova was performed to determine statistical significance. *p ≤0.05;
**p≤0.005; n.s: not significant. (C) N2A, KO, KO + WT cells were cultured and
harvested for RNA isolation, followed by reverse transcription and quantitative
PCR using TaqMan probes for the indicated genes. Actin probe was used to
normalize gene expression. Averages of three independent experiments are
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shown, ± SD. Student’s t-test was performed for individual comparisons
against N2A WT cells.
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Figure 2.6. Proposed model of the role of FUS in the autophagy pathway

We propose that FUS is involved in transcription regulation of genes
involved in autophagy initiation and phagophore elongation. Lack of FUS in
the cells causes downregulation at the gene expression and protein levels,
causing a decrease in autophagosome formation, and thus the reduction in
basal autophagy flux

83

CHAPTER 3. CONCLUSIONS AND FUTURE DIRECTIONS
Altogether, my work showed two novel characteristics of FUS in the cell.
In the first chapter of this dissertation, we showed that FUS can be posttranslationally modified by lysine acetylation. Furthermore, we were able to
identify the acetylated lysine residues in the RRM domain and C-terminal NLS.
We showed that acetylation in K315/K316 in the RRM domain reduced the
RNA binding capabilities of FUS. Additionally, we demonstrated that
acetylation in the NLS affected the interaction between FUS and Transportin1, changing FUS subcellular localization and inducing the inclusion formation.
Interestingly, we found that ALS patient-derived fibroblasts had increased
acetylation at K510, suggesting that the acetylation at this site might be
important in the ALS pathology. The acetylation-mimic mutation in the RRM
domain and treating cells with the deacetylase inhibitor reduced the number of
cells containing cytoplasmic inclusions in cells expressing the ALS mutant
FUS P525L. We also found that CBP/p300 acetylated FUS, more specifically
K510, and found that HDACs and SIRTs played a role in FUS deacetylation.
Our study shows a novel mechanism by which FUS can be regulated
and provides a new avenue for potential therapeutic development in the future.
The fact that FUS acetylation on its RRM domain reduces inclusion formation
in cells expressing mutant FUS suggests that deacetylase inhibitors could be
targeted to this domain in order to prevent aberrant aggregation of FUS in the
cytoplasm in ALS patients. In addition, preventing acetylation in the NLS can
restore the interaction with Transportin-1 and promote FUS nuclear
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localization. Interestingly, we found that ALS patients have higher levels of
acetylation at K510. CBP/p300 acetylates this lysine K510 with higher
specificity, thus we propose that CBP/p300 inhibitor A-485 might serve as a
possible target for future pharmaceutical studies for ALS treatment.
Although this study shows promising findings on FUS regulation, further
investigation is needed to characterize the molecular mechanism that controls
FUS acetylation and the functional consequences of this PTM in different
biological processes where FUS is actively involved. Additional studies are
needed to explore the role of FUS acetylation in modulating protein translation
and NMD pathway, for instance by testing changes in NMD markers when
FUS is acetylated. Since we noticed a change in cytoplasmic aggregation
when FUS is acetylated, it would be interesting to examine how acetylation
can affect stress granule dynamics, and whether FUS acetylation changes the
assembly or disassembly of cytoplasmic aggregates.
The second chapter of this dissertation showed a novel role of FUS in
the autophagy pathway. We found that the ALS mutant FUS did not affect
autophagy flux. However, FUS KO cells showed decreased levels of LC3-II
and were not able to induce autophagy as efficiently as WT N2A cells. We
found that proteins involved in autophagy initiation and phagophore elongation
were lower in FUS KO cells. Furthermore, we found that the transcription of
genes encoding for these proteins were also downregulated. Finally, the
protein and mRNA levels of affected genes were rescued when WT FUS was
overexpressed in KO cells.
85

Previous studies had demonstrated that FUS inclusions co-localized
with autophagosomes and LC3-II marker, suggesting that cytoplasmic protein
aggregates are degraded by the autophagy pathway [157]. However, in this
study we found that FUS is a novel player in regulating autophagy. Our data
indicate that FUS affects transcription of FIP200 and ATG16L1, however
future studies are needed to elucidate the mechanism by which such
transcription downregulation occurs. As discussed in Chapter 1, FUS is
involved in a variety of nuclear functions, including transcription, splicing, and
miRNA processing. All these mechanisms can affect gene expression; thus, it
is necessary to perform next generation sequencing in WT and KO FUS cells
to differentiate gene expression patterns between these two cell populations.
Additionally, it can be useful to determine whether the promoter regions of the
autophagy-related genes contain consensus sequences where FUS can bind
to and regulate transcription.
The two novel findings described in this dissertation may affect each
other although currently there is no evidence. We found that FUS acetylation
at K510 disrupts the interaction with TNPO1, preventing FUS to be shuttled
into the nucleus and promoting FUS accumulation in cytoplasmic aggregates.
A loss-of-function of FUS in the nucleus would disrupt nuclear processes in
which FUS plays an important role, including transcription. It is conceivable
that a loss-of-function in the nucleus would disrupt the transcription of
autophagy genes. Consequently, the autophagy pathway would be impacted,
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and the cells will not be able to clear out cytoplasmic aggregates efficiently.
This hypothesis can be tested in future studies.
Overall, the two projects described in this dissertation open a new
avenue of research that can be further explored and can be translated into
therapeutic interventions. Both projects provide novel insights into the role of
FUS in neurodegenerative diseases, including ALS and FTD. Further
investigation in this field is necessary to find the connection between these two
studies, for instance, to explore how the effect of FUS acetylation on protein
function and inclusion formation will impact the transcription of genes involved
in the autophagy pathway.
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